<html><head>
    <title>Clinical Development Pipeline | Science | Eli Lilly and Company</title><meta data-n-head="1" charset="utf-8"><meta data-n-head="1" name="viewport" content="width=device-width, initial-scale=1"><meta data-n-head="1" data-hid="msvalidate.01" name="msvalidate.01" content="81F1075135E28484F38097FC46C7A6EA"><link data-n-head="1" rel="icon" type="image/x-icon" href="/favicon.ico"><script type="text/javascript" async="" src="https://www.google-analytics.com/analytics.js" nonce=""></script><script type="text/javascript" async="" src="https://www.googletagmanager.com/gtag/js?id=G-BCHTXYH8CC&amp;l=dataLayer&amp;cx=c" nonce=""></script><link rel="preload" href="/_nuxt/8960da8.js" as="script" nonce=""><link rel="preload" href="/_nuxt/2f68ebb.js" as="script" nonce=""><link rel="preload" href="/_nuxt/css/d8dc6b4.css" as="style"><link rel="preload" href="/_nuxt/2e3bd81.js" as="script" nonce=""><link rel="preload" href="/_nuxt/css/c19dd61.css" as="style"><link rel="preload" href="/_nuxt/c9d1dc4.js" as="script" nonce="">
  <link href="/_nuxt/css/d8dc6b4.css" rel="stylesheet"><link href="/_nuxt/css/c19dd61.css" rel="stylesheet"><script charset="utf-8" src="/_nuxt/a23f448.js"></script><link rel="preload" as="style" href="/_nuxt/css/6eeb884.css"><script charset="utf-8" src="/_nuxt/e88fe34.js"></script><script charset="utf-8" src="/_nuxt/f817261.js"></script><script charset="utf-8" src="/_nuxt/528cbbd.js"></script><link data-n-head="1" rel="canonical" href="https://www.lilly.com/discovery/clinical-development-pipeline"><meta data-n-head="1" http-equiv="X-UA-Compatible" content="IE=edge"><meta data-n-head="1" property="og:url" content="https://www.lilly.com/discovery/clinical-development-pipeline"><meta data-n-head="1" data-hid="description" name="description" content="Learn about Lilly's pipeline, including information about our investigational molecules and potential indication data."><meta data-n-head="1" data-hid="page-videos" name="page-has-videos" content="false"><script data-n-head="1" src="//www.googletagmanager.com/gtm.js?id=GTM-PWPQ494&amp;l=dataLayer" async=""></script></head>
  <body>
    <noscript data-n-head="1" data-hid="gtm-noscript" data-pbody="true"><iframe src="//www.googletagmanager.com/ns.html?id=GTM-PWPQ494&l=dataLayer" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><div id="__nuxt"><!----><div id="__layout"><div class="theme-custom"><a href="https://www.lillyhub.com/ux/lillyusa/english/accessibility.html" style="display: none; visibility: hidden;">
    Accessibility Statement
  </a> <div id="header" class="ldc-sticky-header lds-sticky top"><div class="lds-sticky-placeholder" style="height: 184px;"></div> <div class="lds-sticky-container" style="position: fixed;"><div class="lds-skip-to-main"><a href="#main" tabindex="0" class="lds-skip-link">Skip to main content</a> <div class="lds-skip-placeholder"></div></div> <div class="lds-cookie-consent"><div class="lds-cookie-consent-content-container wrapper"><div class="row align-items-center"><div class="lds-cookie-consent-message-container col"><p>
      This website uses cookies and other technologies to personalize content and ads on this and
      other websites and provide social media features. By clicking "I Agree" you consent to our
      use of tracking technologies and disclosure of tracking data to third party ad networks or
      social media companies for the purposes above. If you click "I Disagree" you can still use
      this website. For more information about Lilly's privacy practice and to manage third-party
      preferences, <a href="/privacy" class="lds-link">click here</a>.
      </p></div> <div class="lds-cookie-consent-btn-container col-12 col-md-auto"><button type="button" class="lds-button-base btn-close lds-button secondary" mode="secondary">
            I Disagree
          </button> <button type="button" class="lds-button-base btn-accept lds-button secondary" mode="secondary">
            I Agree
          </button></div></div></div></div> <header id="header-id" class="lds-header lds-header-align-right lds-header-has-exo"><nav aria-label="Global" class="lds-header-exo wrapper"><ul role="menu" class="lds-header-menu lds-header-menu-exo lds-header-menu-right"><!----> <li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="https://esg.lilly.com/?utm_source=lilly.com&amp;utm_medium=referral&amp;utm_campaign=referral_lilly.com" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-82" text="ESG Report" target="_blank"></a> <span id="lds-header-menu-item-link-text-82" class="lds-header-menu-item-link-text">ESG Report</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="https://e.lilly/2DfZjg1" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-85" text="Careers" target="_blank"></a> <span id="lds-header-menu-item-link-text-85" class="lds-header-menu-item-link-text">Careers</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/partners" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-88" text="Partners" target="_self"></a> <span id="lds-header-menu-item-link-text-88" class="lds-header-menu-item-link-text">Partners</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="https://e.lilly/2NcatuX" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-91" text="Investors" target="_blank"></a> <span id="lds-header-menu-item-link-text-91" class="lds-header-menu-item-link-text">Investors</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/contact-us" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-94" text="Contact" target="_self"></a> <span id="lds-header-menu-item-link-text-94" class="lds-header-menu-item-link-text">Contact</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-text"><div class="lds-header-menu-item-content"><!----> <span class="lds-header-menu-item-text" text=""><button type="button" class="lds-button-base countryIconClass" title="Open/close the country selector"><svg aria-labelledby="lds-icon-99-title" aria-hidden="false" title="Globe" role="img" focusable="false" class="ldc-country-selector-icon icon inline icon-globe"><title id="lds-icon-99-title">
    Globe
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m15.9786667 7.46933333c-.26-3.996-3.452-7.188-7.44800003-7.45333333v-.016h-1.06133334v.016c-3.996.26533333-7.188 3.45733333-7.45333333 7.45333333h-.016v1.06133334h.016c.26533333 3.99600003 3.45733333 7.18800003 7.45333333 7.44800003v.0213333h1.06133334v-.0213333c3.99600003-.26 7.18800003-3.452 7.44800003-7.44800003h.0213333v-1.06133334zm-10.96800003-5.724c-.516.68133334-.948 1.54133334-1.256 2.52h-1.59866667c.69333333-1.08266666 1.68266667-1.96266666 2.85466667-2.52zm-3.412 3.588h1.87466666c-.14533333.672-.23333333 1.39066667-.26533333 2.136h-2.12c.05733333-.756.23466667-1.46933333.51066667-2.136zm-.51066667 3.19733334h2.12c.032.74533333.12 1.464.26533333 2.13600003h-1.87466666c-.276-.6666667-.45333334-1.38000003-.51066667-2.13600003zm1.068 3.20400003h1.59333333c.31333334.9786666.74 1.8386666 1.26133334 2.52-1.172-.5573334-2.16133334-1.4373334-2.85466667-2.52zm5.31333333 3.1293333c-1.1-.2906667-2.04266666-1.468-2.61466666-3.1293333h2.61466666zm0-4.1973333h-2.91733333c-.15066667-.6666667-.24533333-1.38000003-.276-2.13600003h3.19333333zm0-3.19733337h-3.19333333c.03066667-.756.12533333-1.46933333.276-2.136h2.91733333zm0-3.204h-2.61466666c.572-1.66133333 1.51466666-2.83866666 2.61466666-3.12933333zm6.37466667 0h-1.5933333c-.3133334-.97866666-.74-1.83866666-1.2613334-2.52 1.172.55733334 2.1613334 1.43733334 2.8546667 2.52zm-5.31333333-3.12933333c1.1.29066667 2.04266663 1.468 2.61466663 3.12933333h-2.61466663zm0 4.19733333h2.91733333c.1506667.66666667.24 1.38.276 2.136h-3.19333333zm0 3.19733334h3.19333333c-.0306667.756-.1253333 1.46933333-.276 2.13600003h-2.91733333zm0 6.33333333v-3.1293333h2.61466663c-.572 1.6613333-1.51466663 2.8386666-2.61466663 3.1293333zm2.45866663-.6093333c.516-.6866667.948-1.5413334 1.2613334-2.52h1.5933333c-.6933333 1.0826666-1.6826667 1.9626666-2.8546667 2.52zm3.412-3.588h-1.8746666c.1453333-.67200003.2333333-1.3906667.2653333-2.13600003h2.12c-.0573333.756-.2346667 1.46933333-.5106667 2.13600003zm-1.6093333-3.19733337c-.032-.74533333-.12-1.464-.2653333-2.136h1.8746666c.276.66666667.4533334 1.38.5106667 2.136z" fill="#212121" fill-rule="evenodd"></path></svg></svg></button></span> <!----></div> <!----> <!----></li></ul></nav> <div class="lds-header-main wrapper"><div class="lds-header-logo-wrapper"><a href="/" class="lds-link lds-logo-lilly logo-md logo-red" aria-label="Visit Lilly.com"><svg viewBox="0 0 631 344" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><title>Lilly</title> <path id="Lilly" d="M435.528098,200.793973 C439.182374,198.191364 443.134091,195.153215 446.820236,192.231919 C475.215236,169.509545 496.917811,144.609478 501.198838,130.831582 C501.358182,130.385421 501.740606,129.121296 501.740606,128.101498 C501.740606,126.67803 501.060741,125.679478 499.754125,125.679478 C486.741077,125.679478 444.886869,167.331852 434.763249,201.048923 L434.763249,201.18702 L435.528098,200.793973 Z M330.648249,196.003047 C370.19729,166.131465 411.732811,122.630707 416.162559,104.77362 C416.311279,104.18936 416.449377,103.615724 416.428131,103.073956 C416.375017,101.905438 415.737643,100.853771 414.250438,100.853771 C401.736667,100.853771 343.767525,154.297559 330.648249,196.003047 Z M87.830101,222.262845 C77.3877946,215.01803 61.2409933,208.686785 46.8257239,208.686785 C32.8353704,208.686785 23.8802694,214.178822 23.8802694,221.104949 C23.8802694,229.082744 34.7474916,232.567054 46.9000842,232.567054 C61.6446633,232.567054 75.0188889,228.583468 87.830101,222.262845 Z M208.984226,128.54766 C237.326111,119.454461 264.223283,100.450101 284.27931,80.606532 C302.826886,62.2395455 317.667071,40.4307407 317.667071,29.6378788 C317.667071,27.173367 315.90367,25.6861616 313.672862,25.6861616 C305.089562,25.6861616 288.79404,37.0951515 266.88963,59.0208081 C249.818636,76.1449158 229.943199,99.4834175 208.984226,128.54766 Z M631,197.086582 C606.662946,221.317407 530.783603,287.91234 510.695707,343.958737 L485.827508,337.553131 C493.954024,314.342104 518.429175,278.245505 545.719394,250.38165 C539.919293,252.580589 533.85362,253.387929 528.998956,253.387929 C521.626667,253.387929 515.890303,251.167744 512.448485,246.982323 C509.962727,243.976044 508.709226,240.045572 508.709226,235.382121 C508.709226,234.372946 508.783586,233.342525 508.921684,232.205875 C484.967054,246.791111 465.686498,253.387929 446.820236,253.387929 C432.139394,253.387929 419.763721,246.982323 414.069848,235.764545 C390.274562,247.55596 367.477828,253.387929 348.399108,253.387929 C330.648249,253.387929 316.349832,246.366195 309.784882,233.54436 C285.734646,247.067306 265.285572,253.387929 249.011296,253.387929 C239.641902,253.387929 232.216498,250.78532 227.436195,245.877542 C223.93064,242.265758 222.071633,237.379226 221.816684,231.749091 C206.392239,241.893956 183.892946,253.387929 160.777525,253.387929 C137.173451,253.387929 121.324091,245.272037 109.033401,237.251751 C89.4235354,248.097727 67.8590572,253.387929 45.0517003,253.387929 C27.8107407,253.387929 0,246.196229 0,221.487374 C0,201.526953 20.8208754,188.025253 48.6634848,188.025253 C72.3525421,188.025253 95.1705219,198.010774 109.490185,208.357475 C123.087492,197.543367 137.35404,182.395118 154.170084,161.011229 C150.473316,161.202441 146.861532,161.30867 143.313485,161.30867 C111.08362,161.30867 84.1758249,151.822424 69.4949832,135.18697 C61.570303,126.210623 57.8204209,115.67271 57.8204209,104.338081 C57.8204209,59.5200842 114.408586,24.7513468 163.921902,19.641734 C167.204377,27.0565152 170.136296,32.771633 173.142576,39.5702862 C124.224141,45.2535354 83.4853367,74.2115488 83.4853367,102.50032 C83.4853367,121.090387 104.401818,139.765438 148.76303,139.765438 C156.358401,139.765438 163.996263,139.043081 171.517273,137.991414 C210.673266,83.9421212 270.703249,0 322.330522,0 C337.616869,0 345.594663,9.28441077 345.594663,21.7238215 C345.594663,47.2825084 323.626515,74.7958081 309.306852,89.1473401 C286.796936,111.763485 246.111246,145.395572 189.257508,156.53899 C167.14064,187.292273 148.964865,207.698855 130.789091,222.432811 C141.815657,228.381633 152.130488,232.014663 164.46367,232.014663 C195.046987,232.014663 224.727357,204.002088 247.917138,180.270539 L248.735101,179.484444 L266.815269,193.612896 L265.976061,194.590202 C255.724966,206.349747 246.281212,218.767912 246.281212,225.715286 C246.281212,231.016111 250.732205,232.057155 254.577694,232.057155 C266.30537,232.057155 284.35367,224.48303 305.610084,211.406246 L305.610084,211.225657 C307.957744,158.695438 379.630421,78.3863468 423.141801,78.3863468 C435.421869,78.3863468 442.486094,84.4945118 442.486094,95.2236364 C442.486094,121.547172 397.05197,178.007862 330.988182,221.200556 L330.988182,221.232424 C334.408754,228.583468 342.28032,232.131515 355.6333,232.131515 C366.064983,232.131515 386.429074,227.478687 410.670522,214.816195 C413.485589,187.600337 428.899411,158.387374 448.445539,137.566498 C468.066027,116.713754 490.055421,103.148316 509.070404,103.148316 C520.787458,103.148316 527.713586,109.61766 527.713586,119.741279 C527.713586,142.697357 501.060741,181.959579 436.845337,223.070185 C439.68165,228.583468 445.205556,232.057155 453.778232,232.057155 C472.899444,232.057155 506.595269,211.639949 532.855067,186.538047 L551.700084,201.18702 C543.647929,210.949461 535.510791,221.699832 535.776364,227.861111 C535.840101,229.858215 537.189209,231.186077 540.354832,231.186077 C559.699125,231.186077 590.165589,205.659259 613.004815,183.117475 L631,197.086582 Z M280.805623,144.407643 C289.346431,144.407643 296.251313,151.355017 296.251313,159.874579 C296.251313,168.42601 289.346431,175.362761 280.805623,175.362761 C272.243569,175.362761 265.317441,168.42601 265.317441,159.874579 C265.317441,151.355017 272.243569,144.407643 280.805623,144.407643 Z"></path></svg></a> <div class="lds-header-mobile-actions"><button type="button" class="lds-button-base lds-header-toggle"><span class="lds-header-toggle-text">
            Menu
          </span> <svg aria-labelledby="lds-icon-18-title" aria-hidden="true" title="Menu" role="img" focusable="false" class="icon inline icon-menu"><title id="lds-icon-18-title">
    Menu
  </title> <!----> <svg viewBox="0 0 16 11" xmlns="http://www.w3.org/2000/svg"><path d="m0 11.0169166h16v-1.83333336h-16zm0-4.58333336h16v-1.83333334h-16zm0-6.41666667v1.83333333h16v-1.83333333z"></path></svg></svg></button> <div aria-live="polite" class="screen-reader-text">
          Menu closed
        </div></div></div> <div class="lds-header-menu-container right" style="visibility: visible;"><nav aria-label="Primary" class="lds-header-menu-wrapper" style="display: none;"><div class="lds-header-menu-container-logo"><div class="row align-items-center justify-content-between"><div class="col-auto"><a href="/" class="lds-link lds-logo-lilly logo-md logo-red" aria-label="Visit Lilly.com"><svg viewBox="0 0 631 344" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><title>Lilly</title> <path id="Lilly" d="M435.528098,200.793973 C439.182374,198.191364 443.134091,195.153215 446.820236,192.231919 C475.215236,169.509545 496.917811,144.609478 501.198838,130.831582 C501.358182,130.385421 501.740606,129.121296 501.740606,128.101498 C501.740606,126.67803 501.060741,125.679478 499.754125,125.679478 C486.741077,125.679478 444.886869,167.331852 434.763249,201.048923 L434.763249,201.18702 L435.528098,200.793973 Z M330.648249,196.003047 C370.19729,166.131465 411.732811,122.630707 416.162559,104.77362 C416.311279,104.18936 416.449377,103.615724 416.428131,103.073956 C416.375017,101.905438 415.737643,100.853771 414.250438,100.853771 C401.736667,100.853771 343.767525,154.297559 330.648249,196.003047 Z M87.830101,222.262845 C77.3877946,215.01803 61.2409933,208.686785 46.8257239,208.686785 C32.8353704,208.686785 23.8802694,214.178822 23.8802694,221.104949 C23.8802694,229.082744 34.7474916,232.567054 46.9000842,232.567054 C61.6446633,232.567054 75.0188889,228.583468 87.830101,222.262845 Z M208.984226,128.54766 C237.326111,119.454461 264.223283,100.450101 284.27931,80.606532 C302.826886,62.2395455 317.667071,40.4307407 317.667071,29.6378788 C317.667071,27.173367 315.90367,25.6861616 313.672862,25.6861616 C305.089562,25.6861616 288.79404,37.0951515 266.88963,59.0208081 C249.818636,76.1449158 229.943199,99.4834175 208.984226,128.54766 Z M631,197.086582 C606.662946,221.317407 530.783603,287.91234 510.695707,343.958737 L485.827508,337.553131 C493.954024,314.342104 518.429175,278.245505 545.719394,250.38165 C539.919293,252.580589 533.85362,253.387929 528.998956,253.387929 C521.626667,253.387929 515.890303,251.167744 512.448485,246.982323 C509.962727,243.976044 508.709226,240.045572 508.709226,235.382121 C508.709226,234.372946 508.783586,233.342525 508.921684,232.205875 C484.967054,246.791111 465.686498,253.387929 446.820236,253.387929 C432.139394,253.387929 419.763721,246.982323 414.069848,235.764545 C390.274562,247.55596 367.477828,253.387929 348.399108,253.387929 C330.648249,253.387929 316.349832,246.366195 309.784882,233.54436 C285.734646,247.067306 265.285572,253.387929 249.011296,253.387929 C239.641902,253.387929 232.216498,250.78532 227.436195,245.877542 C223.93064,242.265758 222.071633,237.379226 221.816684,231.749091 C206.392239,241.893956 183.892946,253.387929 160.777525,253.387929 C137.173451,253.387929 121.324091,245.272037 109.033401,237.251751 C89.4235354,248.097727 67.8590572,253.387929 45.0517003,253.387929 C27.8107407,253.387929 0,246.196229 0,221.487374 C0,201.526953 20.8208754,188.025253 48.6634848,188.025253 C72.3525421,188.025253 95.1705219,198.010774 109.490185,208.357475 C123.087492,197.543367 137.35404,182.395118 154.170084,161.011229 C150.473316,161.202441 146.861532,161.30867 143.313485,161.30867 C111.08362,161.30867 84.1758249,151.822424 69.4949832,135.18697 C61.570303,126.210623 57.8204209,115.67271 57.8204209,104.338081 C57.8204209,59.5200842 114.408586,24.7513468 163.921902,19.641734 C167.204377,27.0565152 170.136296,32.771633 173.142576,39.5702862 C124.224141,45.2535354 83.4853367,74.2115488 83.4853367,102.50032 C83.4853367,121.090387 104.401818,139.765438 148.76303,139.765438 C156.358401,139.765438 163.996263,139.043081 171.517273,137.991414 C210.673266,83.9421212 270.703249,0 322.330522,0 C337.616869,0 345.594663,9.28441077 345.594663,21.7238215 C345.594663,47.2825084 323.626515,74.7958081 309.306852,89.1473401 C286.796936,111.763485 246.111246,145.395572 189.257508,156.53899 C167.14064,187.292273 148.964865,207.698855 130.789091,222.432811 C141.815657,228.381633 152.130488,232.014663 164.46367,232.014663 C195.046987,232.014663 224.727357,204.002088 247.917138,180.270539 L248.735101,179.484444 L266.815269,193.612896 L265.976061,194.590202 C255.724966,206.349747 246.281212,218.767912 246.281212,225.715286 C246.281212,231.016111 250.732205,232.057155 254.577694,232.057155 C266.30537,232.057155 284.35367,224.48303 305.610084,211.406246 L305.610084,211.225657 C307.957744,158.695438 379.630421,78.3863468 423.141801,78.3863468 C435.421869,78.3863468 442.486094,84.4945118 442.486094,95.2236364 C442.486094,121.547172 397.05197,178.007862 330.988182,221.200556 L330.988182,221.232424 C334.408754,228.583468 342.28032,232.131515 355.6333,232.131515 C366.064983,232.131515 386.429074,227.478687 410.670522,214.816195 C413.485589,187.600337 428.899411,158.387374 448.445539,137.566498 C468.066027,116.713754 490.055421,103.148316 509.070404,103.148316 C520.787458,103.148316 527.713586,109.61766 527.713586,119.741279 C527.713586,142.697357 501.060741,181.959579 436.845337,223.070185 C439.68165,228.583468 445.205556,232.057155 453.778232,232.057155 C472.899444,232.057155 506.595269,211.639949 532.855067,186.538047 L551.700084,201.18702 C543.647929,210.949461 535.510791,221.699832 535.776364,227.861111 C535.840101,229.858215 537.189209,231.186077 540.354832,231.186077 C559.699125,231.186077 590.165589,205.659259 613.004815,183.117475 L631,197.086582 Z M280.805623,144.407643 C289.346431,144.407643 296.251313,151.355017 296.251313,159.874579 C296.251313,168.42601 289.346431,175.362761 280.805623,175.362761 C272.243569,175.362761 265.317441,168.42601 265.317441,159.874579 C265.317441,151.355017 272.243569,144.407643 280.805623,144.407643 Z"></path></svg></a></div> <div class="col-auto"><button type="button" class="lds-button-base lds-header-toggle"><span class="lds-header-toggle-text">
                    Close
                  </span> <svg aria-labelledby="lds-icon-24-title" aria-hidden="true" title="Close" role="img" focusable="false" class="icon inline icon-close"><title id="lds-icon-24-title">
    Close
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m15.6464466 1.24644661-.8928932-.89289322c-.1952622-.19526214-.5118446-.19526214-.7071068 0l-6.0464466 6.04644661-6.04644661-6.04644661c-.19526215-.19526214-.51184463-.19526214-.70710678 0l-.89289322.89289322c-.19526214.19526215-.19526214.51184463 0 .70710678l6.04644661 6.04644661-6.04644661 6.0464466c-.19526214.1952622-.19526214.5118446 0 .7071068l.89289322.8928932c.19526215.1952622.51184463.1952622.70710678 0l6.04644661-6.0464466 6.0464466 6.0464466c.1952622.1952622.5118446.1952622.7071068 0l.8928932-.8928932c.1952622-.1952622.1952622-.5118446 0-.7071068l-6.0464466-6.0464466 6.0464466-6.04644661c.1952622-.19526215.1952622-.51184463 0-.70710678z"></path></svg></svg></button></div></div></div> <div class="lds-header-menu-scroll-container" style="height: calc(100% - 104px);"><ul role="menu" class="lds-header-menu lds-header-menu-primary lds-header-menu-right"><!----> <li class="lds-header-menu-item lds-header-menu-item-type-link lds-header-menu-item-has-mega-menu"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-button" text="Company" href="#"><button type="button" class="lds-button-base" aria-labelledby="lds-header-menu-item-button-text-102" tabindex="0"></button> <span id="lds-header-menu-item-button-text-102" class="lds-header-menu-item-link-text">Company</span></div> <div class="lds-header-menu-item-toggle"><div class="lds-header-menu-item-icon-mega-menu-mobile"><!----> <svg aria-labelledby="lds-icon-104-title" aria-hidden="false" title="Expand mega menu" role="img" focusable="false" class="icon icon-chevron-right"><title id="lds-icon-104-title">
    Expand mega menu
  </title> <!----> <svg viewBox="0 0 10 16" xmlns="http://www.w3.org/2000/svg"><path d="m.35614882 13.656239 5.49142273-5.30041676c.198687-.19177614.20428935-.50830906.01251321-.70699605-.00282526-.00292707-.00568614-.00581955-.00858199-.00867679l-5.49077485-5.41756452c-.1965682-.19394729-.19869287-.51052265-.00474557-.70709085.00157122-.00159246.00315312-.00317436.00474557-.00474558l1.17999133-1.16425811c.19470511-.19210905.50764017-.19210905.70234528 0l7.39620755 7.29759144c.1965682.1939473.19869287.51052266.00474557.70709086-.00157122.00159246-.00315311.00317435-.00474557.00474558l-7.38388653 7.28543468c-.1965682.1939473-.51314356.1918226-.70709085-.0047456-.00246518-.0024984-.00490398-.0050228-.007316-.0075727l-1.20082266-1.2694411c-.18841473-.1991813-.18128045-.512943.01599278-.7033545z"></path></svg></svg></div> <div class="lds-header-menu-item-icon-default"><svg aria-labelledby="lds-icon-107-title" aria-hidden="false" title="Expand submenu" role="img" focusable="false" class="icon icon-chevron-down"><title id="lds-icon-107-title">
    Expand submenu
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div></div></div> <!----> <div class="lds-header-mega-menu" style="display: none;"><button type="button" class="lds-button-base lds-header-mega-menu-back"><svg aria-labelledby="lds-icon-112-title" aria-hidden="true" title="Left" role="img" focusable="false" class="icon inline icon-arrow-left"><title id="lds-icon-112-title">
    Left
  </title> <!----> <svg viewBox="0 0 16 12" xmlns="http://www.w3.org/2000/svg"><path d="m14.7422814 5.08593096h-11.5355285l2.78564558-3.35169391c.15396042-.18524546.15396042-.45393188 0-.63917735l-.53645654-.6454655c-.17650395-.21236988-.49174848-.24144496-.70411836-.06494101-.02359344.01960889-.04533213.04134757-.06494101.06494101l-4.43528973 5.3365488c-.15396042.18524546-.15396042.45393189 0 .63917735l4.43528973 5.33654875c.17650395.2123699.49174848.241445.70411836.0649411.02359344-.0196089.04533213-.0413476.06494101-.0649411l.53645654-.6454655c.15396042-.1852454.15396042-.4539318 0-.6391773l-2.78564558-3.35169391h11.5355285c.2761424 0 .5-.22385762.5-.5v-1.03960143c0-.27614238-.2238576-.5-.5-.5z"></path></svg></svg>
    Back
  </button> <div class="lds-header-mega-menu-title">
    Company
  </div> <div class="lds-header-mega-menu-container"><div class="lds-header-mega-menu-wrapper wrapper"><div class="lds-header-mega-menu-content-wrapper lds-header-mega-menu-content-wrapper-full lds-header-mega-menu-content-wrapper-menus"><div class="lds-header-mega-menu-container"><div class="lds-header-mega-menu-container-menus"><div class="lds-header-mega-menu-container-menu column-3"><div class="lds-header-mega-menu-container-menu-title"><div class="lds-header-menu-item-heading">
  WHO WE ARE
</div> <svg aria-labelledby="lds-icon-117-title" aria-hidden="false" title="Expand" role="img" focusable="false" class="icon inline icon-chevron-down"><title id="lds-icon-117-title">
    Expand
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div> <div class="lds-header-mega-menu-menus-container" style="display: none;"><ul role="menu" class="lds-header-menu lds-header-menu-generic lds-header-menu-right"><!----> <li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/who-we-are/about-lilly" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-122" text="About Lilly" target="_self"></a> <span id="lds-header-menu-item-link-text-122" class="lds-header-menu-item-link-text">About Lilly</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/who-we-are/about-lilly/key-facts" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-125" text="Key Facts" target="_self"></a> <span id="lds-header-menu-item-link-text-125" class="lds-header-menu-item-link-text">Key Facts</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/who-we-are/recognitions" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-128" text="Recognitions" target="_self"></a> <span id="lds-header-menu-item-link-text-128" class="lds-header-menu-item-link-text">Recognitions</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/who-we-are/powered-by-purpose" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-131" text="Powered by Purpose" target="_self"></a> <span id="lds-header-menu-item-link-text-131" class="lds-header-menu-item-link-text">Powered by Purpose</span></div> <!----></div> <!----> <!----></li></ul></div></div><div class="lds-header-mega-menu-container-menu column-3"><div class="lds-header-mega-menu-container-menu-title"><div class="lds-header-menu-item-heading">
  LEADERSHIP
</div> <svg aria-labelledby="lds-icon-135-title" aria-hidden="false" title="Expand" role="img" focusable="false" class="icon inline icon-chevron-down"><title id="lds-icon-135-title">
    Expand
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div> <div class="lds-header-mega-menu-menus-container" style="display: none;"><ul role="menu" class="lds-header-menu lds-header-menu-generic lds-header-menu-right"><!----> <li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/leadership/governance" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-140" text="Governance" target="_self"></a> <span id="lds-header-menu-item-link-text-140" class="lds-header-menu-item-link-text">Governance</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/leadership/executive-committee" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-143" text="Executive Committee" target="_self"></a> <span id="lds-header-menu-item-link-text-143" class="lds-header-menu-item-link-text">Executive Committee</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/leadership/board-of-directors" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-146" text="Board of Directors" target="_self"></a> <span id="lds-header-menu-item-link-text-146" class="lds-header-menu-item-link-text">Board of Directors</span></div> <!----></div> <!----> <!----></li></ul></div></div><div class="lds-header-mega-menu-container-menu column-3"><div class="lds-header-mega-menu-container-menu-title"><div class="lds-header-menu-item-heading">
  POLICIES &amp; REPORTS
</div> <svg aria-labelledby="lds-icon-150-title" aria-hidden="false" title="Expand" role="img" focusable="false" class="icon inline icon-chevron-down"><title id="lds-icon-150-title">
    Expand
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div> <div class="lds-header-mega-menu-menus-container" style="display: none;"><ul role="menu" class="lds-header-menu lds-header-menu-generic lds-header-menu-right"><!----> <li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/policies-reports/public-policy" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-155" text="Public Policy" target="_self"></a> <span id="lds-header-menu-item-link-text-155" class="lds-header-menu-item-link-text">Public Policy</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/policies-reports/annual-report" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-158" text="Annual Report &amp; Proxy Statement" target="_self"></a> <span id="lds-header-menu-item-link-text-158" class="lds-header-menu-item-link-text">Annual Report &amp; Proxy Statement</span></div> <!----></div> <!----> <!----></li></ul></div></div></div> <!----></div></div></div></div></div></li><li class="lds-header-menu-item lds-header-menu-item-type-link lds-header-menu-item-has-mega-menu"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-button" text="Science" href="#"><button type="button" class="lds-button-base" aria-labelledby="lds-header-menu-item-button-text-161" tabindex="0"></button> <span id="lds-header-menu-item-button-text-161" class="lds-header-menu-item-link-text">Science</span></div> <div class="lds-header-menu-item-toggle"><div class="lds-header-menu-item-icon-mega-menu-mobile"><!----> <svg aria-labelledby="lds-icon-163-title" aria-hidden="false" title="Expand mega menu" role="img" focusable="false" class="icon icon-chevron-right"><title id="lds-icon-163-title">
    Expand mega menu
  </title> <!----> <svg viewBox="0 0 10 16" xmlns="http://www.w3.org/2000/svg"><path d="m.35614882 13.656239 5.49142273-5.30041676c.198687-.19177614.20428935-.50830906.01251321-.70699605-.00282526-.00292707-.00568614-.00581955-.00858199-.00867679l-5.49077485-5.41756452c-.1965682-.19394729-.19869287-.51052265-.00474557-.70709085.00157122-.00159246.00315312-.00317436.00474557-.00474558l1.17999133-1.16425811c.19470511-.19210905.50764017-.19210905.70234528 0l7.39620755 7.29759144c.1965682.1939473.19869287.51052266.00474557.70709086-.00157122.00159246-.00315311.00317435-.00474557.00474558l-7.38388653 7.28543468c-.1965682.1939473-.51314356.1918226-.70709085-.0047456-.00246518-.0024984-.00490398-.0050228-.007316-.0075727l-1.20082266-1.2694411c-.18841473-.1991813-.18128045-.512943.01599278-.7033545z"></path></svg></svg></div> <div class="lds-header-menu-item-icon-default"><svg aria-labelledby="lds-icon-166-title" aria-hidden="false" title="Expand submenu" role="img" focusable="false" class="icon icon-chevron-down"><title id="lds-icon-166-title">
    Expand submenu
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div></div></div> <!----> <div class="lds-header-mega-menu" style="display: none;"><button type="button" class="lds-button-base lds-header-mega-menu-back"><svg aria-labelledby="lds-icon-171-title" aria-hidden="true" title="Left" role="img" focusable="false" class="icon inline icon-arrow-left"><title id="lds-icon-171-title">
    Left
  </title> <!----> <svg viewBox="0 0 16 12" xmlns="http://www.w3.org/2000/svg"><path d="m14.7422814 5.08593096h-11.5355285l2.78564558-3.35169391c.15396042-.18524546.15396042-.45393188 0-.63917735l-.53645654-.6454655c-.17650395-.21236988-.49174848-.24144496-.70411836-.06494101-.02359344.01960889-.04533213.04134757-.06494101.06494101l-4.43528973 5.3365488c-.15396042.18524546-.15396042.45393189 0 .63917735l4.43528973 5.33654875c.17650395.2123699.49174848.241445.70411836.0649411.02359344-.0196089.04533213-.0413476.06494101-.0649411l.53645654-.6454655c.15396042-.1852454.15396042-.4539318 0-.6391773l-2.78564558-3.35169391h11.5355285c.2761424 0 .5-.22385762.5-.5v-1.03960143c0-.27614238-.2238576-.5-.5-.5z"></path></svg></svg>
    Back
  </button> <div class="lds-header-mega-menu-title">
    Science
  </div> <div class="lds-header-mega-menu-container"><div class="lds-header-mega-menu-wrapper wrapper"><div class="lds-header-mega-menu-content-wrapper lds-header-mega-menu-content-wrapper-full lds-header-mega-menu-content-wrapper-menus"><div class="lds-header-mega-menu-container"><div class="lds-header-mega-menu-container-menus"><div class="lds-header-mega-menu-container-menu column-4"><div class="lds-header-mega-menu-container-menu-title"><div class="lds-header-menu-item-heading">
  DISCOVERY
</div> <svg aria-labelledby="lds-icon-176-title" aria-hidden="false" title="Expand" role="img" focusable="false" class="icon inline icon-chevron-down"><title id="lds-icon-176-title">
    Expand
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div> <div class="lds-header-mega-menu-menus-container" style="display: none;"><ul role="menu" class="lds-header-menu lds-header-menu-generic lds-header-menu-right"><!----> <li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/discovery/clinical-development-pipeline" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-181" text="Clinical Development Pipeline" target="_self"></a> <span id="lds-header-menu-item-link-text-181" class="lds-header-menu-item-link-text">Clinical Development Pipeline</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/discovery/research-and-scientific-discovery" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-184" text="Research &amp; Scientific Discovery" target="_self"></a> <span id="lds-header-menu-item-link-text-184" class="lds-header-menu-item-link-text">Research &amp; Scientific Discovery</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/discovery/medical-research-principles" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-187" text="Principles of Medical Research" target="_self"></a> <span id="lds-header-menu-item-link-text-187" class="lds-header-menu-item-link-text">Principles of Medical Research</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/discovery/research-and-scientific-discovery/elixir-factor-podcast" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-190" text="The Elixir Factor Podcast" target="_self"></a> <span id="lds-header-menu-item-link-text-190" class="lds-header-menu-item-link-text">The Elixir Factor Podcast</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/discovery/100-years-of-insulin" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-193" text="100 Years of Insulin" target="_self"></a> <span id="lds-header-menu-item-link-text-193" class="lds-header-menu-item-link-text">100 Years of Insulin</span></div> <!----></div> <!----> <!----></li></ul></div></div><div class="lds-header-mega-menu-container-menu column-4"><div class="lds-header-mega-menu-container-menu-title"><div class="lds-header-menu-item-heading">
  DISEASE AREAS
</div> <svg aria-labelledby="lds-icon-197-title" aria-hidden="false" title="Expand" role="img" focusable="false" class="icon inline icon-chevron-down"><title id="lds-icon-197-title">
    Expand
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div> <div class="lds-header-mega-menu-menus-container" style="display: none;"><ul role="menu" class="lds-header-menu lds-header-menu-generic lds-header-menu-right"><!----> <li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/disease-areas/alzheimers" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-202" text="Alzheimer's" target="_self"></a> <span id="lds-header-menu-item-link-text-202" class="lds-header-menu-item-link-text">Alzheimer's</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/disease-areas/cancer" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-205" text="Cancer" target="_self"></a> <span id="lds-header-menu-item-link-text-205" class="lds-header-menu-item-link-text">Cancer</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/disease-areas/diabetes" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-208" text="Diabetes" target="_self"></a> <span id="lds-header-menu-item-link-text-208" class="lds-header-menu-item-link-text">Diabetes</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/disease-areas/immunology" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-211" text="Immunology" target="_self"></a> <span id="lds-header-menu-item-link-text-211" class="lds-header-menu-item-link-text">Immunology</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/disease-areas/obesity" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-214" text="Obesity" target="_self"></a> <span id="lds-header-menu-item-link-text-214" class="lds-header-menu-item-link-text">Obesity</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/disease-areas/pain" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-217" text="Pain" target="_self"></a> <span id="lds-header-menu-item-link-text-217" class="lds-header-menu-item-link-text">Pain</span></div> <!----></div> <!----> <!----></li></ul></div></div><div class="lds-header-mega-menu-container-menu column-4"><div class="lds-header-mega-menu-container-menu-title"><div class="lds-header-menu-item-heading">
  CLINICAL RESEARCH
</div> <svg aria-labelledby="lds-icon-221-title" aria-hidden="false" title="Expand" role="img" focusable="false" class="icon inline icon-chevron-down"><title id="lds-icon-221-title">
    Expand
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div> <div class="lds-header-mega-menu-menus-container" style="display: none;"><ul role="menu" class="lds-header-menu lds-header-menu-generic lds-header-menu-right"><!----> <li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/clinical-research/clinical-trials" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-226" text="Clinical Trials" target="_self"></a> <span id="lds-header-menu-item-link-text-226" class="lds-header-menu-item-link-text">Clinical Trials</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/clinical-research/clinical-trial-diversity" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-229" text="Diversity in Clinical Trials" target="_self"></a> <span id="lds-header-menu-item-link-text-229" class="lds-header-menu-item-link-text">Diversity in Clinical Trials</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="https://www.lillytrialguide.com/en-US/" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-232" text="Lilly TrialGuide" target="_blank"></a> <span id="lds-header-menu-item-link-text-232" class="lds-header-menu-item-link-text">Lilly TrialGuide</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/clinical-research/expanded-access" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-235" text="Expanded Access" target="_self"></a> <span id="lds-header-menu-item-link-text-235" class="lds-header-menu-item-link-text">Expanded Access</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/clinical-research/csr-synopses" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-238" text="CSR Synopses" target="_self"></a> <span id="lds-header-menu-item-link-text-238" class="lds-header-menu-item-link-text">CSR Synopses</span></div> <!----></div> <!----> <!----></li></ul></div></div><div class="lds-header-mega-menu-container-menu column-4"><div class="lds-header-mega-menu-container-menu-title"><div class="lds-header-menu-item-heading">
  PARTNERS
</div> <svg aria-labelledby="lds-icon-242-title" aria-hidden="false" title="Expand" role="img" focusable="false" class="icon inline icon-chevron-down"><title id="lds-icon-242-title">
    Expand
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div> <div class="lds-header-mega-menu-menus-container" style="display: none;"><ul role="menu" class="lds-header-menu lds-header-menu-generic lds-header-menu-right"><!----> <li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/partners/collaborate-with-us" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-247" text="Collaborate With Us" target="_self"></a> <span id="lds-header-menu-item-link-text-247" class="lds-header-menu-item-link-text">Collaborate With Us</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/partners/scientific-partnering-areas-of-interest" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-250" text="Scientific Areas of Interest" target="_self"></a> <span id="lds-header-menu-item-link-text-250" class="lds-header-menu-item-link-text">Scientific Areas of Interest</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/partners/our-partnering-approach" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-253" text="Our Approach to Partnering" target="_self"></a> <span id="lds-header-menu-item-link-text-253" class="lds-header-menu-item-link-text">Our Approach to Partnering</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/partners/alliance-management-office" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-256" text="Office of Alliance Management" target="_self"></a> <span id="lds-header-menu-item-link-text-256" class="lds-header-menu-item-link-text">Office of Alliance Management</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/partners/research-award-program" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-259" text="Lilly Research Award Program" target="_self"></a> <span id="lds-header-menu-item-link-text-259" class="lds-header-menu-item-link-text">Lilly Research Award Program</span></div> <!----></div> <!----> <!----></li></ul></div></div></div> <!----></div></div></div></div></div></li><li class="lds-header-menu-item lds-header-menu-item-type-link lds-header-menu-item-has-mega-menu"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-button" text="Medicines" href="#"><button type="button" class="lds-button-base" aria-labelledby="lds-header-menu-item-button-text-262" tabindex="0"></button> <span id="lds-header-menu-item-button-text-262" class="lds-header-menu-item-link-text">Medicines</span></div> <div class="lds-header-menu-item-toggle"><div class="lds-header-menu-item-icon-mega-menu-mobile"><!----> <svg aria-labelledby="lds-icon-264-title" aria-hidden="false" title="Expand mega menu" role="img" focusable="false" class="icon icon-chevron-right"><title id="lds-icon-264-title">
    Expand mega menu
  </title> <!----> <svg viewBox="0 0 10 16" xmlns="http://www.w3.org/2000/svg"><path d="m.35614882 13.656239 5.49142273-5.30041676c.198687-.19177614.20428935-.50830906.01251321-.70699605-.00282526-.00292707-.00568614-.00581955-.00858199-.00867679l-5.49077485-5.41756452c-.1965682-.19394729-.19869287-.51052265-.00474557-.70709085.00157122-.00159246.00315312-.00317436.00474557-.00474558l1.17999133-1.16425811c.19470511-.19210905.50764017-.19210905.70234528 0l7.39620755 7.29759144c.1965682.1939473.19869287.51052266.00474557.70709086-.00157122.00159246-.00315311.00317435-.00474557.00474558l-7.38388653 7.28543468c-.1965682.1939473-.51314356.1918226-.70709085-.0047456-.00246518-.0024984-.00490398-.0050228-.007316-.0075727l-1.20082266-1.2694411c-.18841473-.1991813-.18128045-.512943.01599278-.7033545z"></path></svg></svg></div> <div class="lds-header-menu-item-icon-default"><svg aria-labelledby="lds-icon-267-title" aria-hidden="false" title="Expand submenu" role="img" focusable="false" class="icon icon-chevron-down"><title id="lds-icon-267-title">
    Expand submenu
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div></div></div> <!----> <div class="lds-header-mega-menu" style="display: none;"><button type="button" class="lds-button-base lds-header-mega-menu-back"><svg aria-labelledby="lds-icon-272-title" aria-hidden="true" title="Left" role="img" focusable="false" class="icon inline icon-arrow-left"><title id="lds-icon-272-title">
    Left
  </title> <!----> <svg viewBox="0 0 16 12" xmlns="http://www.w3.org/2000/svg"><path d="m14.7422814 5.08593096h-11.5355285l2.78564558-3.35169391c.15396042-.18524546.15396042-.45393188 0-.63917735l-.53645654-.6454655c-.17650395-.21236988-.49174848-.24144496-.70411836-.06494101-.02359344.01960889-.04533213.04134757-.06494101.06494101l-4.43528973 5.3365488c-.15396042.18524546-.15396042.45393189 0 .63917735l4.43528973 5.33654875c.17650395.2123699.49174848.241445.70411836.0649411.02359344-.0196089.04533213-.0413476.06494101-.0649411l.53645654-.6454655c.15396042-.1852454.15396042-.4539318 0-.6391773l-2.78564558-3.35169391h11.5355285c.2761424 0 .5-.22385762.5-.5v-1.03960143c0-.27614238-.2238576-.5-.5-.5z"></path></svg></svg>
    Back
  </button> <div class="lds-header-mega-menu-title">
    Medicines
  </div> <div class="lds-header-mega-menu-container"><div class="lds-header-mega-menu-wrapper wrapper"><div class="lds-header-mega-menu-content-wrapper lds-header-mega-menu-content-wrapper-full lds-header-mega-menu-content-wrapper-menus"><div class="lds-header-mega-menu-container"><div class="lds-header-mega-menu-container-menus"><div class="lds-header-mega-menu-container-menu column-3"><div class="lds-header-mega-menu-container-menu-title"><div class="lds-header-menu-item-heading">
  SAFETY
</div> <svg aria-labelledby="lds-icon-277-title" aria-hidden="false" title="Expand" role="img" focusable="false" class="icon inline icon-chevron-down"><title id="lds-icon-277-title">
    Expand
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div> <div class="lds-header-mega-menu-menus-container" style="display: none;"><ul role="menu" class="lds-header-menu lds-header-menu-generic lds-header-menu-right"><!----> <li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/safety/patient-safety" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-282" text="Patient Safety" target="_self"></a> <span id="lds-header-menu-item-link-text-282" class="lds-header-menu-item-link-text">Patient Safety</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/safety/medication-safety" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-285" text="Medication Safety" target="_self"></a> <span id="lds-header-menu-item-link-text-285" class="lds-header-menu-item-link-text">Medication Safety</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/our-medicines/manufacturing-quality" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-288" text="Manufacturing &amp; Quality" target="_self"></a> <span id="lds-header-menu-item-link-text-288" class="lds-header-menu-item-link-text">Manufacturing &amp; Quality</span></div> <!----></div> <!----> <!----></li></ul></div></div><div class="lds-header-mega-menu-container-menu column-3"><div class="lds-header-mega-menu-container-menu-title"><div class="lds-header-menu-item-heading">
  OUR MEDICINES
</div> <svg aria-labelledby="lds-icon-292-title" aria-hidden="false" title="Expand" role="img" focusable="false" class="icon inline icon-chevron-down"><title id="lds-icon-292-title">
    Expand
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div> <div class="lds-header-mega-menu-menus-container" style="display: none;"><ul role="menu" class="lds-header-menu lds-header-menu-generic lds-header-menu-right"><!----> <li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/our-medicines/current-medicines" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-297" text="Current Medicines" target="_self"></a> <span id="lds-header-menu-item-link-text-297" class="lds-header-menu-item-link-text">Current Medicines</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/our-medicines/historic-medicines" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-300" text="Historic Medicines" target="_self"></a> <span id="lds-header-menu-item-link-text-300" class="lds-header-menu-item-link-text">Historic Medicines</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/our-medicines/patient-suggestions" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-303" text="Suggestions for Patients" target="_self"></a> <span id="lds-header-menu-item-link-text-303" class="lds-header-menu-item-link-text">Suggestions for Patients</span></div> <!----></div> <!----> <!----></li></ul></div></div><div class="lds-header-mega-menu-container-menu column-3"><div class="lds-header-mega-menu-container-menu-title"><div class="lds-header-menu-item-heading">
  RESOURCES
</div> <svg aria-labelledby="lds-icon-307-title" aria-hidden="false" title="Expand" role="img" focusable="false" class="icon inline icon-chevron-down"><title id="lds-icon-307-title">
    Expand
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div> <div class="lds-header-mega-menu-menus-container" style="display: none;"><ul role="menu" class="lds-header-menu lds-header-menu-generic lds-header-menu-right"><!----> <li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/resources/diabetes-solution-center" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-312" text="Lilly Diabetes Solution Center" target="_self"></a> <span id="lds-header-menu-item-link-text-312" class="lds-header-menu-item-link-text">Lilly Diabetes Solution Center</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/resources/insulin-state-patient-assistance-programs" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-315" text="Lilly Insulin State Patient Assistance Programs" target="_self"></a> <span id="lds-header-menu-item-link-text-315" class="lds-header-menu-item-link-text">Lilly Insulin State Patient Assistance Programs</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="https://e.lilly/2yhbjiw" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-318" text="Lilly Oncology Support Center" target="_blank"></a> <span id="lds-header-menu-item-link-text-318" class="lds-header-menu-item-link-text">Lilly Oncology Support Center</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/resources/lilly-pricing-information" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-321" text="Lilly Pricing Information" target="_self"></a> <span id="lds-header-menu-item-link-text-321" class="lds-header-menu-item-link-text">Lilly Pricing Information</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/resources/lilly-answers-center" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-324" text="The Lilly Answers Center" target="_self"></a> <span id="lds-header-menu-item-link-text-324" class="lds-header-menu-item-link-text">The Lilly Answers Center</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/resources/lilly-cares-foundation" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-327" text="Lilly Cares Foundation" target="_self"></a> <span id="lds-header-menu-item-link-text-327" class="lds-header-menu-item-link-text">Lilly Cares Foundation</span></div> <!----></div> <!----> <!----></li></ul></div></div></div> <!----></div></div></div></div></div></li><li class="lds-header-menu-item lds-header-menu-item-type-link lds-header-menu-item-has-mega-menu"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-button" text="Impact" href="#"><button type="button" class="lds-button-base" aria-labelledby="lds-header-menu-item-button-text-330" tabindex="0"></button> <span id="lds-header-menu-item-button-text-330" class="lds-header-menu-item-link-text">Impact</span></div> <div class="lds-header-menu-item-toggle"><div class="lds-header-menu-item-icon-mega-menu-mobile"><!----> <svg aria-labelledby="lds-icon-332-title" aria-hidden="false" title="Expand mega menu" role="img" focusable="false" class="icon icon-chevron-right"><title id="lds-icon-332-title">
    Expand mega menu
  </title> <!----> <svg viewBox="0 0 10 16" xmlns="http://www.w3.org/2000/svg"><path d="m.35614882 13.656239 5.49142273-5.30041676c.198687-.19177614.20428935-.50830906.01251321-.70699605-.00282526-.00292707-.00568614-.00581955-.00858199-.00867679l-5.49077485-5.41756452c-.1965682-.19394729-.19869287-.51052265-.00474557-.70709085.00157122-.00159246.00315312-.00317436.00474557-.00474558l1.17999133-1.16425811c.19470511-.19210905.50764017-.19210905.70234528 0l7.39620755 7.29759144c.1965682.1939473.19869287.51052266.00474557.70709086-.00157122.00159246-.00315311.00317435-.00474557.00474558l-7.38388653 7.28543468c-.1965682.1939473-.51314356.1918226-.70709085-.0047456-.00246518-.0024984-.00490398-.0050228-.007316-.0075727l-1.20082266-1.2694411c-.18841473-.1991813-.18128045-.512943.01599278-.7033545z"></path></svg></svg></div> <div class="lds-header-menu-item-icon-default"><svg aria-labelledby="lds-icon-335-title" aria-hidden="false" title="Expand submenu" role="img" focusable="false" class="icon icon-chevron-down"><title id="lds-icon-335-title">
    Expand submenu
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div></div></div> <!----> <div class="lds-header-mega-menu" style="display: none;"><button type="button" class="lds-button-base lds-header-mega-menu-back"><svg aria-labelledby="lds-icon-340-title" aria-hidden="true" title="Left" role="img" focusable="false" class="icon inline icon-arrow-left"><title id="lds-icon-340-title">
    Left
  </title> <!----> <svg viewBox="0 0 16 12" xmlns="http://www.w3.org/2000/svg"><path d="m14.7422814 5.08593096h-11.5355285l2.78564558-3.35169391c.15396042-.18524546.15396042-.45393188 0-.63917735l-.53645654-.6454655c-.17650395-.21236988-.49174848-.24144496-.70411836-.06494101-.02359344.01960889-.04533213.04134757-.06494101.06494101l-4.43528973 5.3365488c-.15396042.18524546-.15396042.45393189 0 .63917735l4.43528973 5.33654875c.17650395.2123699.49174848.241445.70411836.0649411.02359344-.0196089.04533213-.0413476.06494101-.0649411l.53645654-.6454655c.15396042-.1852454.15396042-.4539318 0-.6391773l-2.78564558-3.35169391h11.5355285c.2761424 0 .5-.22385762.5-.5v-1.03960143c0-.27614238-.2238576-.5-.5-.5z"></path></svg></svg>
    Back
  </button> <div class="lds-header-mega-menu-title">
    Impact
  </div> <div class="lds-header-mega-menu-container"><div class="lds-header-mega-menu-wrapper wrapper"><div class="lds-header-mega-menu-content-wrapper lds-header-mega-menu-content-wrapper-full lds-header-mega-menu-content-wrapper-menus"><div class="lds-header-mega-menu-container"><div class="lds-header-mega-menu-container-menus"><div class="lds-header-mega-menu-container-menu column-3"><div class="lds-header-mega-menu-container-menu-title"><div class="lds-header-menu-item-heading">
  OUR IMPACT
</div> <svg aria-labelledby="lds-icon-345-title" aria-hidden="false" title="Expand" role="img" focusable="false" class="icon inline icon-chevron-down"><title id="lds-icon-345-title">
    Expand
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div> <div class="lds-header-mega-menu-menus-container" style="display: none;"><ul role="menu" class="lds-header-menu lds-header-menu-generic lds-header-menu-right"><!----> <li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/impact/overview" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-350" text="Overview" target="_self"></a> <span id="lds-header-menu-item-link-text-350" class="lds-header-menu-item-link-text">Overview</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/impact/lilly-foundation" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-353" text="Lilly Foundation" target="_self"></a> <span id="lds-header-menu-item-link-text-353" class="lds-header-menu-item-link-text">Lilly Foundation</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/impact/grant-office" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-356" text="Lilly Grant Office" target="_self"></a> <span id="lds-header-menu-item-link-text-356" class="lds-header-menu-item-link-text">Lilly Grant Office</span></div> <!----></div> <!----> <!----></li></ul></div></div><div class="lds-header-mega-menu-container-menu column-3"><div class="lds-header-mega-menu-container-menu-title"><div class="lds-header-menu-item-heading">
  IMPACT AREAS
</div> <svg aria-labelledby="lds-icon-360-title" aria-hidden="false" title="Expand" role="img" focusable="false" class="icon inline icon-chevron-down"><title id="lds-icon-360-title">
    Expand
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div> <div class="lds-header-mega-menu-menus-container" style="display: none;"><ul role="menu" class="lds-header-menu lds-header-menu-generic lds-header-menu-right"><!----> <li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/impact/access-to-medicines" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-365" text="Increase Access to Medicines" target="_self"></a> <span id="lds-header-menu-item-link-text-365" class="lds-header-menu-item-link-text">Increase Access to Medicines</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/impact/improving-lives-and-communities" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-368" text="Improve Lives and Communities" target="_self"></a> <span id="lds-header-menu-item-link-text-368" class="lds-header-menu-item-link-text">Improve Lives and Communities</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/impact/empowering-a-diverse-workforce" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-371" text="Empower a Diverse Workforce" target="_self"></a> <span id="lds-header-menu-item-link-text-371" class="lds-header-menu-item-link-text">Empower a Diverse Workforce</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/impact/minimizing-our-environmental-impact" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-374" text="Minimize Our Environmental Impact" target="_self"></a> <span id="lds-header-menu-item-link-text-374" class="lds-header-menu-item-link-text">Minimize Our Environmental Impact</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/impact/operating-ethically-and-responsibly" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-377" text="Operate Ethically and Responsibly" target="_self"></a> <span id="lds-header-menu-item-link-text-377" class="lds-header-menu-item-link-text">Operate Ethically and Responsibly</span></div> <!----></div> <!----> <!----></li></ul></div></div><div class="lds-header-mega-menu-container-menu column-3"><div class="lds-header-mega-menu-container-menu-title"><div class="lds-header-menu-item-heading">
  TRANSPARENCY
</div> <svg aria-labelledby="lds-icon-381-title" aria-hidden="false" title="Expand" role="img" focusable="false" class="icon inline icon-chevron-down"><title id="lds-icon-381-title">
    Expand
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div> <div class="lds-header-mega-menu-menus-container" style="display: none;"><ul role="menu" class="lds-header-menu lds-header-menu-generic lds-header-menu-right"><!----> <li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="https://esg.lilly.com" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-386" text="ESG Report" target="_blank"></a> <span id="lds-header-menu-item-link-text-386" class="lds-header-menu-item-link-text">ESG Report</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/impact/minimizing-our-environmental-impact" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-389" text="State-Specific Requirements" target="_self"></a> <span id="lds-header-menu-item-link-text-389" class="lds-header-menu-item-link-text">State-Specific Requirements</span></div> <!----></div> <!----> <!----></li></ul></div></div></div> <!----></div></div></div></div></div></li><li class="lds-header-menu-item lds-header-menu-item-type-link lds-header-menu-item-has-mega-menu"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-button" text="News" href="#"><button type="button" class="lds-button-base" aria-labelledby="lds-header-menu-item-button-text-392" tabindex="0"></button> <span id="lds-header-menu-item-button-text-392" class="lds-header-menu-item-link-text">News</span></div> <div class="lds-header-menu-item-toggle"><div class="lds-header-menu-item-icon-mega-menu-mobile"><!----> <svg aria-labelledby="lds-icon-394-title" aria-hidden="false" title="Expand mega menu" role="img" focusable="false" class="icon icon-chevron-right"><title id="lds-icon-394-title">
    Expand mega menu
  </title> <!----> <svg viewBox="0 0 10 16" xmlns="http://www.w3.org/2000/svg"><path d="m.35614882 13.656239 5.49142273-5.30041676c.198687-.19177614.20428935-.50830906.01251321-.70699605-.00282526-.00292707-.00568614-.00581955-.00858199-.00867679l-5.49077485-5.41756452c-.1965682-.19394729-.19869287-.51052265-.00474557-.70709085.00157122-.00159246.00315312-.00317436.00474557-.00474558l1.17999133-1.16425811c.19470511-.19210905.50764017-.19210905.70234528 0l7.39620755 7.29759144c.1965682.1939473.19869287.51052266.00474557.70709086-.00157122.00159246-.00315311.00317435-.00474557.00474558l-7.38388653 7.28543468c-.1965682.1939473-.51314356.1918226-.70709085-.0047456-.00246518-.0024984-.00490398-.0050228-.007316-.0075727l-1.20082266-1.2694411c-.18841473-.1991813-.18128045-.512943.01599278-.7033545z"></path></svg></svg></div> <div class="lds-header-menu-item-icon-default"><svg aria-labelledby="lds-icon-397-title" aria-hidden="false" title="Expand submenu" role="img" focusable="false" class="icon icon-chevron-down"><title id="lds-icon-397-title">
    Expand submenu
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div></div></div> <!----> <div class="lds-header-mega-menu" style="display: none;"><button type="button" class="lds-button-base lds-header-mega-menu-back"><svg aria-labelledby="lds-icon-402-title" aria-hidden="true" title="Left" role="img" focusable="false" class="icon inline icon-arrow-left"><title id="lds-icon-402-title">
    Left
  </title> <!----> <svg viewBox="0 0 16 12" xmlns="http://www.w3.org/2000/svg"><path d="m14.7422814 5.08593096h-11.5355285l2.78564558-3.35169391c.15396042-.18524546.15396042-.45393188 0-.63917735l-.53645654-.6454655c-.17650395-.21236988-.49174848-.24144496-.70411836-.06494101-.02359344.01960889-.04533213.04134757-.06494101.06494101l-4.43528973 5.3365488c-.15396042.18524546-.15396042.45393189 0 .63917735l4.43528973 5.33654875c.17650395.2123699.49174848.241445.70411836.0649411.02359344-.0196089.04533213-.0413476.06494101-.0649411l.53645654-.6454655c.15396042-.1852454.15396042-.4539318 0-.6391773l-2.78564558-3.35169391h11.5355285c.2761424 0 .5-.22385762.5-.5v-1.03960143c0-.27614238-.2238576-.5-.5-.5z"></path></svg></svg>
    Back
  </button> <div class="lds-header-mega-menu-title">
    News
  </div> <div class="lds-header-mega-menu-container"><div class="lds-header-mega-menu-wrapper wrapper"><div class="lds-header-mega-menu-content-wrapper lds-header-mega-menu-content-wrapper-full lds-header-mega-menu-content-wrapper-menus"><div class="lds-header-mega-menu-container"><div class="lds-header-mega-menu-container-menus"><div class="lds-header-mega-menu-container-menu column-3"><div class="lds-header-mega-menu-container-menu-title"><div class="lds-header-menu-item-heading">
  STORIES
</div> <svg aria-labelledby="lds-icon-407-title" aria-hidden="false" title="Expand" role="img" focusable="false" class="icon inline icon-chevron-down"><title id="lds-icon-407-title">
    Expand
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div> <div class="lds-header-mega-menu-menus-container" style="display: none;"><ul role="menu" class="lds-header-menu lds-header-menu-generic lds-header-menu-right"><!----> <li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/news/stories/tags/caring" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-412" text="Caring" target="_self"></a> <span id="lds-header-menu-item-link-text-412" class="lds-header-menu-item-link-text">Caring</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/news/stories/tags/science" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-415" text="Science" target="_self"></a> <span id="lds-header-menu-item-link-text-415" class="lds-header-menu-item-link-text">Science</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/news/stories/tags/policy" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-418" text="Policy" target="_self"></a> <span id="lds-header-menu-item-link-text-418" class="lds-header-menu-item-link-text">Policy</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/news/stories" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-421" text="All Stories" target="_self"></a> <span id="lds-header-menu-item-link-text-421" class="lds-header-menu-item-link-text">All Stories</span></div> <!----></div> <!----> <!----></li></ul></div></div><div class="lds-header-mega-menu-container-menu column-3"><div class="lds-header-mega-menu-container-menu-title"><div class="lds-header-menu-item-heading">
  PRESS RELEASES
</div> <svg aria-labelledby="lds-icon-425-title" aria-hidden="false" title="Expand" role="img" focusable="false" class="icon inline icon-chevron-down"><title id="lds-icon-425-title">
    Expand
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div> <div class="lds-header-mega-menu-menus-container" style="display: none;"><ul role="menu" class="lds-header-menu lds-header-menu-generic lds-header-menu-right"><!----> <li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/news/press-releases" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-430" text="Recent" target="_self"></a> <span id="lds-header-menu-item-link-text-430" class="lds-header-menu-item-link-text">Recent</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="http://lilly.mediaroom.com/" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-433" text="Archives" target="_blank"></a> <span id="lds-header-menu-item-link-text-433" class="lds-header-menu-item-link-text">Archives</span></div> <!----></div> <!----> <!----></li></ul></div></div><div class="lds-header-mega-menu-container-menu column-3"><div class="lds-header-mega-menu-container-menu-title"><div class="lds-header-menu-item-heading">
  MEDIA
</div> <svg aria-labelledby="lds-icon-437-title" aria-hidden="false" title="Expand" role="img" focusable="false" class="icon inline icon-chevron-down"><title id="lds-icon-437-title">
    Expand
  </title> <!----> <svg viewBox="0 0 16 10" xmlns="http://www.w3.org/2000/svg"><path d="m13.7774151.39471485-5.42149688 5.49476037c-.1939473.19656821-.51052266.19869287-.70709086.00474558-.00159246-.00157123-.00317435-.00315312-.00474558-.00474558l-5.4214969-5.49476037c-.19394729-.1965682-.51052265-.19869287-.70709085-.00474558-.00159246.00157123-.00317436.00315312-.00474558.00474558l-1.16425811 1.17999133c-.19210905.19470511-.19210905.50764017 0 .70234528l7.29759144 7.39620755c.1939473.1965682.51052266.19869287.70709086.00474557.00159246-.00157122.00317435-.00315312.00474558-.00474557l7.29759148-7.39620755c.192109-.19470511.192109-.50764017 0-.70234528l-1.1642582-1.17999133c-.1939472-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div> <div class="lds-header-mega-menu-menus-container" style="display: none;"><ul role="menu" class="lds-header-menu lds-header-menu-generic lds-header-menu-right"><!----> <li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/news" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-442" text="All News" target="_self"></a> <span id="lds-header-menu-item-link-text-442" class="lds-header-menu-item-link-text">All News</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/news/media/media-kits" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-445" text="Media Kits" target="_self"></a> <span id="lds-header-menu-item-link-text-445" class="lds-header-menu-item-link-text">Media Kits</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/news/media/media-contacts" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-448" text="Media Contacts" target="_self"></a> <span id="lds-header-menu-item-link-text-448" class="lds-header-menu-item-link-text">Media Contacts</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/lilly-corporate-social-media-guidelines" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-451" text="Social Media Guidelines" target="_self"></a> <span id="lds-header-menu-item-link-text-451" class="lds-header-menu-item-link-text">Social Media Guidelines</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="#" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-454" text="" target="_self"></a> <span id="lds-header-menu-item-link-text-454" class="lds-header-menu-item-link-text"></span></div> <!----></div> <!----> <!----></li></ul></div></div></div> <!----></div></div></div></div></div></li><li class="lds-header-menu-item lds-header-menu-item-type-text"><div class="lds-header-menu-item-content"><!----> <span class="lds-header-menu-item-text" text=""><button type="button" class="lds-button-base searchIconClass" title="Open/close the search"><svg aria-labelledby="lds-icon-459-title" aria-hidden="false" title="Search" role="img" focusable="false" class="icon inline icon-search"><title id="lds-icon-459-title">
    Search
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m11.4225165 10.2340685h-.5371891l-.2790745-.279111c.9303698-1.02340684 1.4885918-2.41896163 1.4885918-3.90755341-.0000365-3.3493315-2.69810911-6.04740409-6.04744061-6.04740409s-6.04740409 2.69807259-6.04740409 6.04740409 2.69807259 6.04740411 6.04740409 6.04740411c1.48859178 0 2.88414657-.5582219 3.90755341-1.4885918l.279111.2790745v.5371902c0 .1326076.0526778.259784.1464452.353552l4.1518507 4.1518861c.1952613.1952629.5118438.1952641.7071068.0000027.0000004-.0000004.0000009-.0000009.0000013-.0000014l.6884467-.6884493c.1952621-.1952622.1952621-.5118447 0-.7071068l-4.1518493-4.1518493c-.0937682-.0937682-.2209452-.1464466-.3535534-.1464466zm-5.37511241 0c-2.32592465 0-4.18666437-1.86073976-4.18666437-4.18666441s1.86073972-4.18666437 4.18666437-4.18666437 4.18666441 1.86073972 4.18666441 4.18666437-1.86073976 4.18666441-4.18666441 4.18666441z"></path></svg></svg></button></span> <!----></div> <!----> <!----></li></ul> <ul role="menu" class="lds-header-menu lds-header-menu-exo lds-header-menu-right"><!----> <li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="https://esg.lilly.com/?utm_source=lilly.com&amp;utm_medium=referral&amp;utm_campaign=referral_lilly.com" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-462" text="ESG Report" target="_blank"></a> <span id="lds-header-menu-item-link-text-462" class="lds-header-menu-item-link-text">ESG Report</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="https://e.lilly/2DfZjg1" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-465" text="Careers" target="_blank"></a> <span id="lds-header-menu-item-link-text-465" class="lds-header-menu-item-link-text">Careers</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/partners" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-468" text="Partners" target="_self"></a> <span id="lds-header-menu-item-link-text-468" class="lds-header-menu-item-link-text">Partners</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="https://e.lilly/2NcatuX" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-471" text="Investors" target="_blank"></a> <span id="lds-header-menu-item-link-text-471" class="lds-header-menu-item-link-text">Investors</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-link"><div class="lds-header-menu-item-content"><!----> <div class="lds-header-menu-item-link"><a href="/contact-us" tabindex="0" class="lds-link" aria-labelledby="lds-header-menu-item-link-text-474" text="Contact" target="_self"></a> <span id="lds-header-menu-item-link-text-474" class="lds-header-menu-item-link-text">Contact</span></div> <!----></div> <!----> <!----></li><li class="lds-header-menu-item lds-header-menu-item-type-text"><div class="lds-header-menu-item-content"><!----> <span class="lds-header-menu-item-text" text=""><button type="button" class="lds-button-base countryIconClass" title="Open/close the country selector"><svg aria-labelledby="lds-icon-479-title" aria-hidden="false" title="Globe" role="img" focusable="false" class="ldc-country-selector-icon icon inline icon-globe"><title id="lds-icon-479-title">
    Globe
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m15.9786667 7.46933333c-.26-3.996-3.452-7.188-7.44800003-7.45333333v-.016h-1.06133334v.016c-3.996.26533333-7.188 3.45733333-7.45333333 7.45333333h-.016v1.06133334h.016c.26533333 3.99600003 3.45733333 7.18800003 7.45333333 7.44800003v.0213333h1.06133334v-.0213333c3.99600003-.26 7.18800003-3.452 7.44800003-7.44800003h.0213333v-1.06133334zm-10.96800003-5.724c-.516.68133334-.948 1.54133334-1.256 2.52h-1.59866667c.69333333-1.08266666 1.68266667-1.96266666 2.85466667-2.52zm-3.412 3.588h1.87466666c-.14533333.672-.23333333 1.39066667-.26533333 2.136h-2.12c.05733333-.756.23466667-1.46933333.51066667-2.136zm-.51066667 3.19733334h2.12c.032.74533333.12 1.464.26533333 2.13600003h-1.87466666c-.276-.6666667-.45333334-1.38000003-.51066667-2.13600003zm1.068 3.20400003h1.59333333c.31333334.9786666.74 1.8386666 1.26133334 2.52-1.172-.5573334-2.16133334-1.4373334-2.85466667-2.52zm5.31333333 3.1293333c-1.1-.2906667-2.04266666-1.468-2.61466666-3.1293333h2.61466666zm0-4.1973333h-2.91733333c-.15066667-.6666667-.24533333-1.38000003-.276-2.13600003h3.19333333zm0-3.19733337h-3.19333333c.03066667-.756.12533333-1.46933333.276-2.136h2.91733333zm0-3.204h-2.61466666c.572-1.66133333 1.51466666-2.83866666 2.61466666-3.12933333zm6.37466667 0h-1.5933333c-.3133334-.97866666-.74-1.83866666-1.2613334-2.52 1.172.55733334 2.1613334 1.43733334 2.8546667 2.52zm-5.31333333-3.12933333c1.1.29066667 2.04266663 1.468 2.61466663 3.12933333h-2.61466663zm0 4.19733333h2.91733333c.1506667.66666667.24 1.38.276 2.136h-3.19333333zm0 3.19733334h3.19333333c-.0306667.756-.1253333 1.46933333-.276 2.13600003h-2.91733333zm0 6.33333333v-3.1293333h2.61466663c-.572 1.6613333-1.51466663 2.8386666-2.61466663 3.1293333zm2.45866663-.6093333c.516-.6866667.948-1.5413334 1.2613334-2.52h1.5933333c-.6933333 1.0826666-1.6826667 1.9626666-2.8546667 2.52zm3.412-3.588h-1.8746666c.1453333-.67200003.2333333-1.3906667.2653333-2.13600003h2.12c-.0573333.756-.2346667 1.46933333-.5106667 2.13600003zm-1.6093333-3.19733337c-.032-.74533333-.12-1.464-.2653333-2.136h1.8746666c.276.66666667.4533334 1.38.5106667 2.136z" fill="#212121" fill-rule="evenodd"></path></svg></svg></button></span> <!----></div> <!----> <!----></li></ul></div></nav></div></div> <!----></header> <!----> <!----></div></div> <div id="main"><div data-v-41887d52="" class="page-container"><div data-v-41887d52="" class="mb-5 ldc-pipeline"><div data-v-41887d52="" class="ewi-cdp-pipeline"><!----> <div class="container"><section><div class="container"><div class="row align-center"><div class="col-12"><h1 class="heading" data-gtm-vis-recent-on-screen-13399482_372="1661" data-gtm-vis-first-on-screen-13399482_372="1661" data-gtm-vis-total-visible-time-13399482_372="1000" data-gtm-vis-recent-on-screen-13399482_390="1661" data-gtm-vis-first-on-screen-13399482_390="1661" data-gtm-vis-total-visible-time-13399482_390="1000" data-gtm-vis-recent-on-screen-13399482_392="1661" data-gtm-vis-first-on-screen-13399482_392="1661" data-gtm-vis-total-visible-time-13399482_392="1000" data-gtm-vis-recent-on-screen-13399482_391="1661" data-gtm-vis-first-on-screen-13399482_391="1661" data-gtm-vis-total-visible-time-13399482_391="1000" data-gtm-vis-has-fired-13399482_372="1" data-gtm-vis-has-fired-13399482_390="1" data-gtm-vis-has-fired-13399482_392="1" data-gtm-vis-has-fired-13399482_391="1" style="font-weight: 400;">
                Medicines in Development
              </h1> <p class="paragraph-optional">
                Molecule &amp; Potential Indication Data as of April 28, 2022
              </p> <div class="pipeline-cta">
                Interested in Lilly clinical trials? Learn more at
                <a href="https://www.lillytrialguide.com/en-US?utm_source=ldc&amp;utm_medium=organic&amp;utm_campaign=ltg&amp;utm_content=cdp" target="_blank" class="lds-link">
                  LillyTrialGuide.com
                </a></div></div></div></div></section> <section><h3 class="bolder align-center">
          Molecule Group Filters
        </h3> <div class="pipeline d-flex"><p class="pipeline-label">
            Therapeutic Areas:
          </p> <div class="pipeline-filter"><button type="button" class="lds-button-base button-icon-right ldc-custom area lds-button cancer">
              Cancer
            </button><button type="button" class="lds-button-base button-icon-right ldc-custom area lds-button diabetes">
              Diabetes
            </button><button type="button" class="lds-button-base button-icon-right ldc-custom area lds-button immunology">
              Immunology
            </button><button type="button" class="lds-button-base button-icon-right ldc-custom area lds-button neurodegeneration">
              Neurodegeneration
            </button><button type="button" class="lds-button-base button-icon-right ldc-custom area lds-button pain">
              Pain
            </button></div></div> <div class="pipeline d-flex"><p class="pipeline-label">
            Type:
          </p> <div class="pipeline-filter"><button type="button" class="lds-button-base button-icon-right ldc-custom lds-button nme">
              NME
            </button><button type="button" class="lds-button-base button-icon-right ldc-custom lds-button nilex">
              NILEX
            </button> <button type="button" class="lds-button-base button-icon-right ldc-custom lds-button large molecule">
              Large Molecule
            </button><button type="button" class="lds-button-base button-icon-right ldc-custom lds-button small molecule">
              Small Molecule
            </button></div></div></section> <section><div class="mb-2 align-items-center row"><div class="col col-12 col-md-auto"><span class="d-block d-md-inline mr-3 legend-check"><span class="icon icon-pipeline-check"></span>
              regulatory approval achieved
            </span> <span class="d-block d-md-inline mr-3 legend-bookmark"><span class="icon icon-pipeline-bookmark"></span>
              milestone achieved
            </span> <span class="d-block d-md-inline mr-3 legend-plus"><span class="icon icon-pipeline-plus"></span>
              new to pipeline
            </span></div> <div class="align-right faq-wrap col col-12 col-md"><a href="#faqs" class="lds-link d-flex align-items-center justify-content-end"><svg aria-labelledby="lds-icon-507-title" aria-hidden="false" title="Information" role="img" focusable="false" class="icon inline icon-info-filled-circle"><title id="lds-icon-507-title">
    Information
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m7.99788393 0c-4.41665344 0-7.99788393 3.58123049-7.99788393 7.99788393 0 4.41749987 3.58123049 8.00211607 7.99788393 8.00211607 4.41749987 0 8.00211607-3.5846162 8.00211607-8.00211607 0-4.41665344-3.5846162-7.99788393-8.00211607-7.99788393zm1.66661377 12.3993017c-.41305613.1616675-.74062318.2843993-.98524044.3698884-.24461726.0863355-.52901656.1295032-.8531979.1295032-.49939164 0-.88874782-.1227318-1.16383643-.3673491-.27762789-.2412315-.41305613-.55187-.41305613-.9259906 0-.1455853.01015712-.2937099.02962493-.4460667.02031423-.1523568.05332487-.3207957.0990319-.5129345l.51632016-1.82150978c.04570703-.17521029.08548907-.34026345.115114-.49262022.03047135-.15912818.04655346-.30048141.04655346-.42998466 0-.23107443-.04909274-.39358832-.14558536-.48584881-.09564619-.09226048-.27762789-.13542824-.54848437-.13542824-.13204253 0-.27085648.01946781-.41051685.05924986-.13881394.04316775-.25731365.08294979-.35634555.11934613l.13542824-.55864148c.33687774-.13881395.66105909-.25477438.96831191-.35380628.30809924-.09987832.59842353-.14897106.87351214-.14897106.4951595 0 .87605142.12188542 1.14352219.36057769.26747077.23784584.40374544.54848437.40374544.93191557 0 .07956409-.01015712.21837803-.02708565.41644183-.01946781.20229593-.05247844.3834312-.10241761.5493308l-.51208802 1.81473835c-.04316776.1455854-.07956409.3140243-.11596043.4993917-.03301064.1853674-.04909274.327567-.04909274.4232132 0 .2412316.05586415.4071312.16166746.4926202.10918902.0897213.29455642.1320426.56202719.1320426.12527112 0 .26493149-.0228535.42321325-.0660213.15574247-.0423213.27085648-.0821034.34364915-.115114zm-.08887478-7.36644977c-.24123155.22091731-.52901656.33349204-.86674073.33349204-.33349204 0-.62466275-.11257473-.8658943-.33349204-.23784585-.22176374-.36057769-.49262022-.36057769-.81003016 0-.31487065.12273184-.58572713.36057769-.81087658.24123155-.22091731.53240226-.33349203.8658943-.33349203.33772417 0 .62550918.11257472.86674073.33349203.23784584.22514945.35719198.49600593.35719198.81087658 0 .31740994-.11934614.58826642-.35719198.81003016z" fill-rule="evenodd"></path></svg></svg> <label for="info-icon" class="faqlabel">FAQ</label></a></div></div> <div><div><div class="card portfolio-card mb-4"><div class="row header mx-0"><h3 class="mb-0">
        Regulatory Approval Achieved
      </h3> <div class="portfolio-wrap"><span class="view-text d-none d-lg-block">view portfolio</span> <div class="icon-wrap-accordion rotate-reverse"><svg aria-labelledby="lds-icon-510-title" aria-hidden="false" title="Down" role="img" focusable="false" class="icon icon-chevron-outlined-down"><title id="lds-icon-510-title">
    Down
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m8 0c-4.4 0-8 3.6-8 8s3.6 8 8 8 8-3.6 8-8-3.6-8-8-8zm0 14.4c-3.52 0-6.4-2.88-6.4-6.4s2.88-6.4 6.4-6.4 6.4 2.88 6.4 6.4-2.88 6.4-6.4 6.4zm2.5083399-8.25117257-2.35483024 2.38665226c-.19394729.19656821-.51052265.19869287-.70709085.00474558-.00159246-.00157122-.00317436-.00315312-.00474558-.00474558l-2.35483023-2.38665226c-.1939473-.1965682-.51052266-.19869287-.70709086-.00474558-.00159246.00157123-.00317435.00315312-.00474558.00474558l-.23092478.23404538c-.19210904.19470512-.19210904.50764017 0 .70234528l3.29759145 3.34215351c.19394729.1965682.51052265.1986929.70709086.0047456.00159245-.0015713.00317435-.0031532.00474557-.0047456l3.29759144-3.34215351c.1921091-.19470511.1921091-.50764016 0-.70234528l-.2309248-.23404538c-.1939473-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div></div></div> <div class="row ml-2 mr-0"><div class="pipeline-card mb-3" type="nme" phase="5" title="Bebtelovimab" page_id="68" body_html="<p>Bebtelovimab (LY-CoV1404; LY3853113) is a potent, neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2 that maintains binding and neutralizing activity across currently known and reported variants of concern. Bebtelovimab is being studied for the treatment of mild to moderate COVID-19 both as a monotherapy and together with other mAbs. &amp;quot;Approval&amp;quot; reflects Emergency Use Authorization in the US, not full FDA approval.</p>" created_at="2022-04-22 17:23:35" updated_at="2022-04-26 13:49:54" featured_links="" referencetitle="Bebtelovimab/COVID-19" clinical_studies="" therapeutic_area_id="207" regulatory_approval_achieved="true"><div class="smallCard"><div class="card flex-column collapsed Immunology"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Bebtelovimab
          </a> <div class="icon-wrap"><span class="icon icon-pipeline-check"></span></div></div> <div class="indication fadeIn smallCard">
          COVID-19
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="5" title="Empagliflozin" page_id="68" body_html="<p>BI10773 (Empagliflozin) is a chemical entity that inhibits the sodium glucose co-transporter-2 (SGLT 2). BI10773 is being studied in collaboration with Boehringer Ingelheim as a treatment for chronic heart failure with preserved ejection fraction.</p>" created_at="2022-04-22 17:23:35" updated_at="2022-04-22 19:02:13" featured_links="" referencetitle="Empagliflozin/HFpEF" clinical_studies="" therapeutic_area_id="206" regulatory_approval_achieved="true"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Empagliflozin
          </a> <div class="icon-wrap"><span class="icon icon-pipeline-check"></span></div></div> <div class="indication fadeIn smallCard">
          HFpEF
        </div></div> <!----></div></div></div> <!----></div></div></div></div><div><div><div class="card portfolio-card mb-4"><div class="row header mx-0"><h3 class="mb-0">
        Regulatory Review
      </h3> <div class="portfolio-wrap"><span class="view-text d-none d-lg-block">view portfolio</span> <div class="icon-wrap-accordion rotate-reverse"><svg aria-labelledby="lds-icon-520-title" aria-hidden="false" title="Down" role="img" focusable="false" class="icon icon-chevron-outlined-down"><title id="lds-icon-520-title">
    Down
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m8 0c-4.4 0-8 3.6-8 8s3.6 8 8 8 8-3.6 8-8-3.6-8-8-8zm0 14.4c-3.52 0-6.4-2.88-6.4-6.4s2.88-6.4 6.4-6.4 6.4 2.88 6.4 6.4-2.88 6.4-6.4 6.4zm2.5083399-8.25117257-2.35483024 2.38665226c-.19394729.19656821-.51052265.19869287-.70709085.00474558-.00159246-.00157122-.00317436-.00315312-.00474558-.00474558l-2.35483023-2.38665226c-.1939473-.1965682-.51052266-.19869287-.70709086-.00474558-.00159246.00157123-.00317435.00315312-.00474558.00474558l-.23092478.23404538c-.19210904.19470512-.19210904.50764017 0 .70234528l3.29759145 3.34215351c.19394729.1965682.51052265.1986929.70709086.0047456.00159245-.0015713.00317435-.0031532.00474557-.0047456l3.29759144-3.34215351c.1921091-.19470511.1921091-.50764016 0-.70234528l-.2309248-.23404538c-.1939473-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div></div></div> <div class="row ml-2 mr-0"><div class="pipeline-card mb-3" type="indication" phase="4" title="Baricitinib" page_id="68" body_html="<p>LY3009104 (baricitinib, formerly known as JAK1/JAK2 Inhibitor) is a chemical entity that inhibits the activity of the Janus (JAK) 1 and 2 enzymes. LY3009104 is being studied for the treatment of alopecia areata.</p>" created_at="2022-04-22 17:23:35" updated_at="2022-04-22 17:23:35" featured_links="" referencetitle="Baricitinib/Alopecia Areata" clinical_studies="" therapeutic_area_id="207"><div class="smallCard"><div class="card flex-column collapsed Immunology"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Baricitinib
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Alopecia Areata
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="formulation" phase="4" title="Connected Care Pre-Filled Insulin Pen  " page_id="68" body_html="<p>This prefilled insulin pen is part of the integrated insulin management system, which includes a Bluetooth-enabled pen attachment and mobile medical application</p>" created_at="2022-04-22 17:23:35" updated_at="2022-04-22 17:23:35" featured_links="" referencetitle="Connected Care Pre-Filled Insulin Pen  /Diabetes" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Connected Care Pre-Filled Insulin Pen  
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard hideIndication">
          Diabetes
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="4" title="Mirikizumab" page_id="68" body_html="<p>LY3074828 (formerly known as IL-23 antibody) is a biologic entity that blocks the activity of the cytokine interleukin 23. LY3074828 is being studied for the treatment of ulcerative colitis.</p>" created_at="2022-04-22 17:23:34" updated_at="2022-04-22 18:55:17" featured_links="" referencetitle="Mirikizumab/Ulcerative Colitis" clinical_studies="" therapeutic_area_id="207"><div class="smallCard"><div class="card flex-column collapsed Immunology"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Mirikizumab
          </a> <div class="icon-wrap"><span class="icon icon-pipeline-bookmark"></span></div></div> <div class="indication fadeIn smallCard">
          Ulcerative Colitis
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="4" title="Sintilimab" page_id="68" body_html="<p>LY3342901 (sintilimab), a biologic entity, is a recombinant, fully human immunoglobulin G4 monoclonal antibody which binds to PD-1 molecules on the surface of T-cells and blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway to restore antitumor immunity. LY3342901, in combination with pemetrexed and platinum chemotherapy, is being studied in collaboration with Innovent for the treatment of first-line nonsquamous non-small cell lung cancer (NSCLC).&nbsp;This US regulatory submission received a complete response letter from the FDA. Along with Innovent, Lilly is assessing next steps for sintilimab in the U.S.</p>" created_at="2022-04-27 14:13:07" updated_at="2022-04-27 14:16:47" featured_links="" referencetitle="Sintilimab/1L NonSquam NSCLC" clinical_studies="" therapeutic_area_id="205"><div class="smallCard"><div class="card flex-column collapsed Cancer"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Sintilimab
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          1L NonSquam NSCLC
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="4" title=" Tirzepatide" page_id="68" body_html="<p>LY3298176 (Dual GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as a coagonist for both the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of diabetes.</p>" created_at="2022-04-22 17:23:35" updated_at="2022-04-22 17:23:35" featured_links="" referencetitle=" Tirzepatide/Diabetes" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
             Tirzepatide
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Diabetes
        </div></div> <!----></div></div></div> <!----></div></div></div></div><div><div><div class="card portfolio-card mb-4"><div class="row header mx-0"><h3 class="mb-0">
        Phase 3
      </h3> <div class="portfolio-wrap"><span class="view-text d-none d-lg-block">view portfolio</span> <div class="icon-wrap-accordion rotate-reverse"><svg aria-labelledby="lds-icon-535-title" aria-hidden="false" title="Down" role="img" focusable="false" class="icon icon-chevron-outlined-down"><title id="lds-icon-535-title">
    Down
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m8 0c-4.4 0-8 3.6-8 8s3.6 8 8 8 8-3.6 8-8-3.6-8-8-8zm0 14.4c-3.52 0-6.4-2.88-6.4-6.4s2.88-6.4 6.4-6.4 6.4 2.88 6.4 6.4-2.88 6.4-6.4 6.4zm2.5083399-8.25117257-2.35483024 2.38665226c-.19394729.19656821-.51052265.19869287-.70709085.00474558-.00159246-.00157122-.00317436-.00315312-.00474558-.00474558l-2.35483023-2.38665226c-.1939473-.1965682-.51052266-.19869287-.70709086-.00474558-.00159246.00157123-.00317435.00315312-.00474558.00474558l-.23092478.23404538c-.19210904.19470512-.19210904.50764017 0 .70234528l3.29759145 3.34215351c.19394729.1965682.51052265.1986929.70709086.0047456.00159245-.0015713.00317435-.0031532.00474557-.0047456l3.29759144-3.34215351c.1921091-.19470511.1921091-.50764016 0-.70234528l-.2309248-.23404538c-.1939473-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div></div></div> <div class="row ml-2 mr-0"><div class="pipeline-card mb-3" type="indication" phase="3" title="Abemaciclib" page_id="68" body_html="<p>LY2835219 (abemaciclib), a chemical entity, is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. LY2835219 is being studied for the treatment of metastatic castrate-resistant prostate cancer.</p>" created_at="2022-04-22 17:23:34" updated_at="2022-04-27 18:05:33" featured_links="" referencetitle="Abemaciclib/Castrate Resistant Prostate Cancer" clinical_studies="" therapeutic_area_id="205"><div class="smallCard"><div class="card flex-column collapsed Cancer"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Abemaciclib
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Castrate Resistant Prostate Cancer
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="3" title="Abemaciclib" page_id="68" body_html="<p>LY2835219 (abemaciclib), a chemical entity, is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. LY2835219 is being studied for the treatment of HR+ HER2- advanced or metastatic breast cancer in combination with fulvestrant following progression on a CDK4 &amp;amp; 6 inhibitor and endocrine therapy.</p>" created_at="2022-04-22 18:45:26" updated_at="2022-04-22 18:48:08" featured_links="" referencetitle="Abemaciclib/MBC Sequencing" clinical_studies="" therapeutic_area_id="205"><div class="smallCard"><div class="card flex-column collapsed Cancer"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Abemaciclib
          </a> <div class="icon-wrap"><span class="icon icon-pipeline-plus"></span></div></div> <div class="indication fadeIn smallCard">
          MBC Sequencing
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="3" title="Abemaciclib " page_id="68" body_html="<p>LY2835219 (abemaciclib), a chemical entity, is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. LY2835219 is being studied for the treatment of men with high-risk metastatic hormone-sensitive prostate cancer in combination with abiraterone.</p>" created_at="2022-04-27 18:00:20" updated_at="2022-04-27 18:03:58" featured_links="" referencetitle="Abemaciclib /Hormone Sensitive Prostate Cancer" clinical_studies="" therapeutic_area_id="205"><div class="smallCard"><div class="card flex-column collapsed Cancer"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Abemaciclib 
          </a> <div class="icon-wrap"><span class="icon icon-pipeline-plus"></span></div></div> <div class="indication fadeIn smallCard">
          Hormone Sensitive Prostate Cancer
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="3" title="Basal Insulin-Fc" page_id="68" body_html="<p>LY3209590 &amp;quot;Basal insulin-Fc&amp;quot; is a large molecule comprised of an engineered insulin fused to an Fc domain designed to provide a long-acting basal profile. LY3209590 is being studied for the treatment of diabetes.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 18:40:58" featured_links="" referencetitle="Basal Insulin-Fc/Diabetes" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Basal Insulin-Fc
          </a> <div class="icon-wrap"><span class="icon icon-pipeline-bookmark"></span></div></div> <div class="indication fadeIn smallCard">
          Diabetes
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="3" title="Donanemab" page_id="68" body_html="<p>LY3002813 (N3pG-Ab MAb) is a biologic entity that binds to deposited amyloid plaque in brain and is being studied for the treatment of preclinical Alzheimer's disease.</p>" created_at="2022-04-22 17:23:34" updated_at="2022-04-22 19:48:45" featured_links="" referencetitle="Donanemab/Preclinical Alzheimer's Disease " clinical_studies="" therapeutic_area_id="208"><div class="smallCard"><div class="card flex-column collapsed Neurodegeneration"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Donanemab
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Preclinical Alzheimer's Disease 
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="3" title="Donanemab " page_id="68" body_html="<p>LY3002813 (N3pG-Ab MAb) is a biologic entity that binds to deposited amyloid plaque in brain and is being studied for the treatment of early Alzheimer's disease.</p>" created_at="2022-04-22 17:23:34" updated_at="2022-04-26 13:55:26" featured_links="" referencetitle="Donanemab /Early Alzheimer's Disease " clinical_studies="" therapeutic_area_id="208"><div class="smallCard"><div class="card flex-column collapsed Neurodegeneration"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Donanemab 
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Early Alzheimer's Disease 
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="3" title="Empagliflozin" page_id="68" body_html="<p>BI10773 (Empagliflozin) is a chemical entity that inhibits the sodium glucose co-transporter-2 (SGLT 2). BI10773 is being studied in collaboration with Boehringer Ingelheim as a treatment for chronic kidney disease.</p>" created_at="2022-04-22 17:23:34" updated_at="2022-04-22 17:23:34" featured_links="" referencetitle="Empagliflozin/Chronic Kidney Disease" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Empagliflozin
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Chronic Kidney Disease
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="3" title="Empagliflozin" page_id="68" body_html="<p>BI10773 (Empagliflozin) is a chemical entity that inhibits the sodium glucose co-transporter-2 (SGLT 2). BI10773 is being studied in collaboration with Boehringer Ingelheim as a treatment to lower the risk of heart failure and death for post myocardial infarction patients.</p>" created_at="2022-04-22 17:23:34" updated_at="2022-04-22 17:23:34" featured_links="" referencetitle="Empagliflozin/Post MI" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Empagliflozin
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Post MI
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="3" title="Imlunestrant" page_id="68" body_html="<p>LY3484356 “Imlunestrant&amp;quot; is a chemical entity that functions as an oral Selective Estrogen Receptor Degrader (SERD). It is being studied for the treatment of 2nd line Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor 2 negative (HER2-) metastatic Breast Cancer (mBC).</p>" created_at="2022-04-22 17:23:34" updated_at="2022-04-22 17:23:34" featured_links="" referencetitle="Imlunestrant/ER+ HER2- mBC" clinical_studies="" therapeutic_area_id="205"><div class="smallCard"><div class="card flex-column collapsed Cancer"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Imlunestrant
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          ER+ HER2- mBC
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="3" title="Lebrikizumab   " page_id="68" body_html="<p>&amp;quot;Lebrikizumab&amp;quot; is monoclonal antibody designed to bind IL-13 with very high affinity  inhibiting the biological effects of IL-13. It is being studied for the treatment of moderate-to-severe atopic dermatitis.</p>" created_at="2022-04-22 17:23:34" updated_at="2022-04-22 17:23:34" featured_links="" referencetitle="Lebrikizumab   / Atopic Dermatitis" clinical_studies="" therapeutic_area_id="207"><div class="smallCard"><div class="card flex-column collapsed Immunology"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Lebrikizumab   
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
           Atopic Dermatitis
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="3" title="Mirikizumab" page_id="68" body_html="<p>LY3074828 (formerly known as IL-23 antibody) is a  biologic entity that blocks the activity of the cytokine interleukin 23. LY3074828 is being studied for the treatment of Crohn's disease.</p>" created_at="2022-04-22 17:23:34" updated_at="2022-04-22 17:23:34" featured_links="" referencetitle="Mirikizumab/Crohn's Disease" clinical_studies="" therapeutic_area_id="207"><div class="smallCard"><div class="card flex-column collapsed Immunology"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Mirikizumab
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Crohn's Disease
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="3" title="Pirtobrutinib" page_id="68" body_html="<p>&amp;quot;Pirtobrutinib&amp;quot; is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied in combination with Venetoclax and Rituximab for the treatment of&nbsp; R/R CLL.</p>" created_at="2022-04-22 17:23:35" updated_at="2022-04-22 17:23:35" featured_links="" referencetitle="Pirtobrutinib/R/R CLL combination" clinical_studies="" therapeutic_area_id="205"><div class="smallCard"><div class="card flex-column collapsed Cancer"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Pirtobrutinib
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          R/R CLL combination
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="3" title="Pirtobrutinib" page_id="68" body_html="<p>&amp;quot;Pirtobrutinib&amp;quot; is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied as a monotherapy for the treatment of  R/R CLL in BTK pre-treated patients.</p>" created_at="2022-04-22 17:23:35" updated_at="2022-04-22 17:23:35" featured_links="" referencetitle="Pirtobrutinib/ R/R CLL monotherapy" clinical_studies="" therapeutic_area_id="205"><div class="smallCard"><div class="card flex-column collapsed Cancer"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Pirtobrutinib
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
           R/R CLL monotherapy
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="3" title="Pirtobrutinib" page_id="68" body_html="<p>&amp;quot;Pirtobrutinib&amp;quot; is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied as a monotherapy for the treatment of&nbsp;R/R MCL in BTKi treatment naïve patients.</p>" created_at="2022-04-22 17:23:35" updated_at="2022-04-22 17:23:35" featured_links="" referencetitle="Pirtobrutinib/R/R MCL monotherapy" clinical_studies="" therapeutic_area_id="205"><div class="smallCard"><div class="card flex-column collapsed Cancer"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Pirtobrutinib
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          R/R MCL monotherapy
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="3" title="Pirtobrutinib " page_id="68" body_html="<p>&amp;quot;Pirtobrutinib&amp;quot; is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied for the treatment of&nbsp;patients with R/R MCL who have received prior BTKi therapies. Rolling submission in the U.S. has been initiated based on the Phase 2 study. </p>" created_at="2022-04-22 17:23:34" updated_at="2022-04-27 17:58:30" featured_links="" referencetitle="Pirtobrutinib /R/R MCL (Prior BTK)" clinical_studies="" therapeutic_area_id="205"><div class="smallCard"><div class="card flex-column collapsed Cancer"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Pirtobrutinib 
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          R/R MCL (Prior BTK)
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="3" title="Pirtobrutinib   " page_id="68" body_html="<p>&amp;quot;Pirtobrutinib&amp;quot; is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied as a first line treatment of CLL.</p>" created_at="2022-04-22 17:23:35" updated_at="2022-04-27 21:29:13" featured_links="" referencetitle="Pirtobrutinib   /1L CLL monotherapy " clinical_studies="" therapeutic_area_id="205"><div class="smallCard"><div class="card flex-column collapsed Cancer"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Pirtobrutinib   
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          1L CLL monotherapy 
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="3" title="Selpercatinib" page_id="68" body_html="<p>LY3527723 &amp;quot;RET inhibitor&amp;quot; is a chemical entity that inhibits the rearranged during transfection (RET) kinase. It is being studied in the treatment of advanced or metastatic, treatment-naïve RET fusion-positive NSCLC.</p>" created_at="2022-04-22 17:23:35" updated_at="2022-04-22 17:23:35" featured_links="" referencetitle="Selpercatinib/ 1L NSCLC" clinical_studies="" therapeutic_area_id="205"><div class="smallCard"><div class="card flex-column collapsed Cancer"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Selpercatinib
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
           1L NSCLC
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="3" title="Selpercatinib " page_id="68" body_html="<p>LY3527723 &amp;quot;Selpercatinib&amp;quot; is a chemical entity that inhibits the rearranged during transfection (RET) kinase. It is being studied in the treatment of adjuvant RET fusion+ non small cell lung cancer after surgery / chemotherapy / radiotherapy.</p>" created_at="2022-04-22 17:23:35" updated_at="2022-04-22 19:39:52" featured_links="" referencetitle="Selpercatinib /Adjuvant RET+ NSCLC" clinical_studies="" therapeutic_area_id="205"><div class="smallCard"><div class="card flex-column collapsed Cancer"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Selpercatinib 
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Adjuvant RET+ NSCLC
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="3" title="Selpercatinib  " page_id="68" body_html="<p>LY3527723 &amp;quot;RET inhibitor&amp;quot; is a chemical entity that inhibits the rearranged during transfection (RET) kinase. It is being studied in the treatment of advanced or metastatic, treatment-naïve RET-mutant medullary thyroid cancer.</p>" created_at="2022-04-22 17:23:35" updated_at="2022-04-22 17:23:35" featured_links="" referencetitle="Selpercatinib  / 1L Medullary Thyroid Cancer" clinical_studies="" therapeutic_area_id="205"><div class="smallCard"><div class="card flex-column collapsed Cancer"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Selpercatinib  
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
           1L Medullary Thyroid Cancer
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="3" title="Solanezumab" page_id="68" body_html="<p>LY2062430 (solanezumab) is a large molecule that binds to soluble monomeric forms of amyloid ß (Ab) after it is produced. LY2062430 is being studied for its potential to slow the progression of Alzheimer's disease. </p>" created_at="2022-04-22 17:23:35" updated_at="2022-04-22 18:42:46" featured_links="" referencetitle="Solanezumab/Preclinical Alzheimer’s Disease" clinical_studies="" therapeutic_area_id="208"><div class="smallCard"><div class="card flex-column collapsed Neurodegeneration"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Solanezumab
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Preclinical Alzheimer’s Disease
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="3" title="Tirzepatide" page_id="68" body_html="<p>LY3298176 (Dual GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as a coagonist for both the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of chronic heart failure with preserved ejection fraction.</p>" created_at="2022-04-22 17:23:35" updated_at="2022-04-22 17:23:35" featured_links="" referencetitle="Tirzepatide/HFpEF" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Tirzepatide
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          HFpEF
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="3" title=" Tirzepatide " page_id="68" body_html="<p>LY3298176 (Dual GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as a coagonist for both the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of obesity.</p>" created_at="2022-04-22 17:23:35" updated_at="2022-04-22 17:23:35" featured_links="" referencetitle=" Tirzepatide /  Obesity" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
             Tirzepatide 
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
            Obesity
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="3" title=" Tirzepatide  " page_id="68" body_html="<p>LY3298176 (Dual GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as a coagonist for both the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the reduction of adverse CV outcomes.</p>" created_at="2022-04-22 17:23:35" updated_at="2022-04-22 17:23:35" featured_links="" referencetitle=" Tirzepatide  /CV Outcomes" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
             Tirzepatide  
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          CV Outcomes
        </div></div> <!----></div></div></div> <!----></div></div></div></div><div><div><div class="card portfolio-card mb-4"><div class="row header mx-0"><h3 class="mb-0">
        Phase 2
      </h3> <div class="portfolio-wrap"><span class="view-text d-none d-lg-block">view portfolio</span> <div class="icon-wrap-accordion rotate-reverse"><svg aria-labelledby="lds-icon-588-title" aria-hidden="false" title="Down" role="img" focusable="false" class="icon icon-chevron-outlined-down"><title id="lds-icon-588-title">
    Down
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m8 0c-4.4 0-8 3.6-8 8s3.6 8 8 8 8-3.6 8-8-3.6-8-8-8zm0 14.4c-3.52 0-6.4-2.88-6.4-6.4s2.88-6.4 6.4-6.4 6.4 2.88 6.4 6.4-2.88 6.4-6.4 6.4zm2.5083399-8.25117257-2.35483024 2.38665226c-.19394729.19656821-.51052265.19869287-.70709085.00474558-.00159246-.00157122-.00317436-.00315312-.00474558-.00474558l-2.35483023-2.38665226c-.1939473-.1965682-.51052266-.19869287-.70709086-.00474558-.00159246.00157123-.00317435.00315312-.00474558.00474558l-.23092478.23404538c-.19210904.19470512-.19210904.50764017 0 .70234528l3.29759145 3.34215351c.19394729.1965682.51052265.1986929.70709086.0047456.00159245-.0015713.00317435-.0031532.00474557-.0047456l3.29759144-3.34215351c.1921091-.19470511.1921091-.50764016 0-.70234528l-.2309248-.23404538c-.1939473-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div></div></div> <div class="row ml-2 mr-0"><div class="pipeline-card mb-3" type="nme" phase="2" title="CXCR1/2 Ligands Monoclonal Antibody" page_id="68" body_html="<p>LY3041658 (CXCR1/2L antibody) neutralizes chemokines that bind to the CXCR1 or CXCR2 receptors.  LY3041658 is being studied for the treatment of hidradenitis suppurativa.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="CXCR1/2 Ligands Monoclonal Antibody/Hidradenitis Suppurativa " clinical_studies="" therapeutic_area_id="207"><div class="smallCard"><div class="card flex-column collapsed Immunology"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            CXCR1/2 Ligands Monoclonal Antibody
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard hideIndication">
          Hidradenitis Suppurativa 
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="2" title="GBA1 Gene Therapy" page_id="68" body_html="<p>&amp;quot;GBA1 Gene Therapy&amp;quot; is a gene therapy  being developed for patients with neuronopathic Gaucher disease (nGD).</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="GBA1 Gene Therapy/Gaucher Disease Type 2" clinical_studies="" therapeutic_area_id="208"><div class="smallCard"><div class="card flex-column collapsed Neurodegeneration"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            GBA1 Gene Therapy
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Gaucher Disease Type 2
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="2" title="GBA1 Gene Therapy   " page_id="68" body_html="<p>&amp;quot;GBA1 Gene Therapy&amp;quot; is a gene therapy  being developed for patients with Parkinson's disease with GBA1 mutations (PD-GBA).</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="GBA1 Gene Therapy   /Parkinson's" clinical_studies="" therapeutic_area_id="208"><div class="smallCard"><div class="card flex-column collapsed Neurodegeneration"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            GBA1 Gene Therapy   
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Parkinson's
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="2" title="GGG Tri-Agonist" page_id="68" body_html="<p>LY3437943 (GIP/GLP-1/Glucagon Receptor Agonist) is a biologic entity that acts as a triagonist for the gastric inhibitory polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. It is being studied for the treatment of T2DM.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="GGG Tri-Agonist/Diabetes" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            GGG Tri-Agonist
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Diabetes
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="2" title="GGG Tri-Agonist" page_id="68" body_html="<p>LY3437943 (GIP/GLP-1/Glucagon Receptor Agonist) is a biologic entity that acts as a triagonist for the gastric inhibitory polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor.&nbsp; It is being studied for the treatment of obesity.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="GGG Tri-Agonist/Obesity" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            GGG Tri-Agonist
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Obesity
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="2" title="GLP-1 Receptor NPA" page_id="68" body_html="<p>LY3502970 (GLP-1 Receptor Non-peptide Agonist) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor. It is being studied for the treatment of obesity.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="GLP-1 Receptor NPA/Obesity" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            GLP-1 Receptor NPA
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Obesity
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="2" title="GLP-1 Receptor NPA  " page_id="68" body_html="<p>LY3502970 (GLP-1 Receptor Non-peptide Agonist) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor.  It is being studied for the treatment of type 2 diabetes.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="GLP-1 Receptor NPA  /Diabetes" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            GLP-1 Receptor NPA  
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Diabetes
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="2" title="GRN Gene Therapy  " page_id="68" body_html="<p>&amp;quot;GRN Gene Therapy&amp;quot; is a gene therapy being developed for patients with frontotemporal dementia with GRN mutations (FTD-GRN).</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="GRN Gene Therapy  /Frontotemporal Dementia" clinical_studies="" therapeutic_area_id="208"><div class="smallCard"><div class="card flex-column collapsed Neurodegeneration"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            GRN Gene Therapy  
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Frontotemporal Dementia
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="2" title="IL-2 Conjugate" page_id="68" body_html="<p>LY3471851 (IL-2 Conjugate), a large molecule, targets the IL-2 receptor complex in order to stimulate selective proliferation of immune regulatory T cells. LY3454738 is being studied for the treatment of systemic lupus erythematosus</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="IL-2 Conjugate/Systemic Lupus Erythematosus" clinical_studies="" therapeutic_area_id="207"><div class="smallCard"><div class="card flex-column collapsed Immunology"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            IL-2 Conjugate
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Systemic Lupus Erythematosus
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="2" title="Mevidalen (D1 PAM)" page_id="68" body_html="<p>LY3154207 (Mevidalen formally called D1 PAM) is a chemical entity that acts as a positive allosteric modulator of the dopamine receptor D1 and is being studied for the treatment of symptomatic lewy body dementia.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="Mevidalen (D1 PAM)/Symptomatic LBD" clinical_studies="" therapeutic_area_id="208"><div class="smallCard"><div class="card flex-column collapsed Neurodegeneration"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Mevidalen (D1 PAM)
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Symptomatic LBD
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="2" title="O-GlcNAcase Inhibitor   " page_id="68" body_html="<p>LY3372689 (O-GlcNAcase Inhibitor) is an oral anti-tau small molecule that inhibits the OGA enzyme and is intended to slow the accumulation of hyper-phosphorylated, insoluble tau aggregates.&nbsp;It is being studied for the treatment of Alzheimer's disease.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 19:41:57" featured_links="" referencetitle="O-GlcNAcase Inhibitor   /Alzheimer's" clinical_studies="" therapeutic_area_id="208"><div class="smallCard"><div class="card flex-column collapsed Neurodegeneration"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            O-GlcNAcase Inhibitor   
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Alzheimer's
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="2" title="PACAP38 Antibody" page_id="68" body_html="<p>LY3451838 is a ligand-directed, fully human antibody for the PACAP38 neuropeptide.  It is being studied for the prevention of migraine.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="PACAP38 Antibody/Migraine" clinical_studies="" therapeutic_area_id="209"><div class="smallCard"><div class="card flex-column collapsed Pain"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            PACAP38 Antibody
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Migraine
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="2" title="Peresolimab (PD-1 Antibody Agonist)" page_id="68" body_html="<p>LY3462817 &amp;quot;Peresolimab (PD-1 Antibody Agonist)&amp;quot; is a monoclonal antibody that binds to and agonizes the PD-1 inhibitory receptor to suppress T-cell activation. LY3462817 is being studied for the treatment of rheumatoid arthritis and other autoimmune diseases.</p>" created_at="2022-04-22 17:23:34" updated_at="2022-04-26 13:54:02" featured_links="" referencetitle="Peresolimab (PD-1 Antibody Agonist)/Rheumatoid Arthritis" clinical_studies="" therapeutic_area_id="207"><div class="smallCard"><div class="card flex-column collapsed Immunology"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Peresolimab (PD-1 Antibody Agonist)
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard hideIndication">
          Rheumatoid Arthritis
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="2" title="Pirtobrutinib" page_id="68" body_html="<p>&amp;quot;Pirtobrutinib&amp;quot; is a chemical entity that inhibits the Bruton's tyrosine kinase. It is being studied for the treatment of  B-Cell Malignancies.</p>" created_at="2022-04-22 17:23:34" updated_at="2022-04-22 17:23:34" featured_links="" referencetitle="Pirtobrutinib/B-Cell Malignancies" clinical_studies="" therapeutic_area_id="205"><div class="smallCard"><div class="card flex-column collapsed Cancer"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Pirtobrutinib
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          B-Cell Malignancies
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="2" title="SSTR4 Agonist " page_id="68" body_html="<p>LY3556050 is a small molecule SSTR4 agonist designed to modulate somatostatin signaling, impacting nerve excitability, resulting in improved regulation of inflammation and pain.  It is being developed for treatment of pain.</p>" created_at="2022-04-22 17:23:34" updated_at="2022-04-22 17:23:34" featured_links="" referencetitle="SSTR4 Agonist /Pain" clinical_studies="" therapeutic_area_id="209"><div class="smallCard"><div class="card flex-column collapsed Pain"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            SSTR4 Agonist 
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Pain
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="indication" phase="2" title=" Tirzepatide   " page_id="68" body_html="<p>LY3298176 (Dual GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as a coagonist for both the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of non-alcoholic steatohepatitis (NASH).</p>" created_at="2022-04-22 17:23:34" updated_at="2022-04-22 17:23:34" featured_links="" referencetitle=" Tirzepatide   /NASH" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
             Tirzepatide   
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          NASH
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="2" title="TRPA1 Antagonist " page_id="68" body_html="<p>LY3526318 is an oral, highly selective, small molecule antagonist of transient receptor potential ankyrin 1 (TRPA1), a calcium-permeable nonselective cation channel expressed in pain sensing peripheral nerves.  It is being developed as a non-opioid treatment for chronic pain conditions.</p>" created_at="2022-04-22 17:23:34" updated_at="2022-04-22 17:23:34" featured_links="" referencetitle="TRPA1 Antagonist /Pain" clinical_studies="" therapeutic_area_id="209"><div class="smallCard"><div class="card flex-column collapsed Pain"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            TRPA1 Antagonist 
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Pain
        </div></div> <!----></div></div></div> <!----></div></div></div></div><div><div><div class="card portfolio-card mb-4"><div class="row header mx-0"><h3 class="mb-0">
        Phase 1
      </h3> <div class="portfolio-wrap"><span class="view-text d-none d-lg-block">view portfolio</span> <div class="icon-wrap-accordion rotate-reverse"><svg aria-labelledby="lds-icon-626-title" aria-hidden="false" title="Down" role="img" focusable="false" class="icon icon-chevron-outlined-down"><title id="lds-icon-626-title">
    Down
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m8 0c-4.4 0-8 3.6-8 8s3.6 8 8 8 8-3.6 8-8-3.6-8-8-8zm0 14.4c-3.52 0-6.4-2.88-6.4-6.4s2.88-6.4 6.4-6.4 6.4 2.88 6.4 6.4-2.88 6.4-6.4 6.4zm2.5083399-8.25117257-2.35483024 2.38665226c-.19394729.19656821-.51052265.19869287-.70709085.00474558-.00159246-.00157122-.00317436-.00315312-.00474558-.00474558l-2.35483023-2.38665226c-.1939473-.1965682-.51052266-.19869287-.70709086-.00474558-.00159246.00157123-.00317435.00315312-.00474558.00474558l-.23092478.23404538c-.19210904.19470512-.19210904.50764017 0 .70234528l3.29759145 3.34215351c.19394729.1965682.51052265.1986929.70709086.0047456.00159245-.0015713.00317435-.0031532.00474557-.0047456l3.29759144-3.34215351c.1921091-.19470511.1921091-.50764016 0-.70234528l-.2309248-.23404538c-.1939473-.1965682-.5105226-.19869287-.7070908-.00474558-.0015925.00157123-.0031744.00315312-.0047456.00474558z"></path></svg></svg></div></div></div> <div class="row ml-2 mr-0"><div class="pipeline-card mb-3" type="nme" phase="1" title="Amylin Agonist Long Acting" page_id="68" body_html="<p>&amp;quot;Amylin Agonist Long Acting&amp;quot; is a biological entity being studied for the treatment of obesity.</p>" created_at="2022-04-22 18:13:51" updated_at="2022-04-26 13:53:16" featured_links="" referencetitle="Amylin Agonist Long Acting/Obesity " clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Amylin Agonist Long Acting
          </a> <div class="icon-wrap"><span class="icon icon-pipeline-plus"></span></div></div> <div class="indication fadeIn smallCard">
          Obesity 
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="ANGPTL3 siRNA  " page_id="68" body_html="<p>&amp;quot;ANGPTL3 siRNA &amp;quot; is a small interfering RNA (siRNA) being studied for the treatment of cardiovascular disease.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="ANGPTL3 siRNA  /CVD" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            ANGPTL3 siRNA  
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          CVD
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="BCL2 (LOXO-338)" page_id="68" body_html="<p>&amp;quot;BCL2 (LOXO-338)&amp;quot; is a chemical entity being studied for the treatment of cancer.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 19:45:00" featured_links="" referencetitle="BCL2 (LOXO-338)/Cancer" clinical_studies="" therapeutic_area_id="205"><div class="smallCard"><div class="card flex-column collapsed Cancer"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            BCL2 (LOXO-338)
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Cancer
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="BTLA Antibody Agonist" page_id="68" body_html="<p>&amp;quot;BTLA Agonist Antibody&amp;quot; is a biologic entity being studied for the treatment of autoimmune diseases.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="BTLA Antibody Agonist/Immunology" clinical_studies="" therapeutic_area_id="207"><div class="smallCard"><div class="card flex-column collapsed Immunology"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            BTLA Antibody Agonist
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Immunology
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="CD19 Antibody" page_id="68" body_html="<p>&amp;quot;CD19 Antibody&amp;quot; is a biologic entity being studied for the treatment of autoimmune diseases.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 19:45:30" featured_links="" referencetitle="CD19 Antibody/Immunology" clinical_studies="" therapeutic_area_id="207"><div class="smallCard"><div class="card flex-column collapsed Immunology"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            CD19 Antibody
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Immunology
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="CD200R Antibody Agonist" page_id="68" body_html="<p>&amp;quot;CD200R Antibody Agonist&amp;quot; is a biologic entity being studied for the treatment of autoimmune diseases.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="CD200R Antibody Agonist/Immunology" clinical_studies="" therapeutic_area_id="207"><div class="smallCard"><div class="card flex-column collapsed Immunology"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            CD200R Antibody Agonist
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Immunology
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="GIP/GLP Coagonist Peptide    " page_id="68" body_html="<p>&amp;quot;GIP/GLP Coagonist Peptide&amp;quot; is a biologic entity being studied for the treatment of diabetes.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="GIP/GLP Coagonist Peptide    / Diabetes" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            GIP/GLP Coagonist Peptide    
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
           Diabetes
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="GIPR Agonist Long Acting  " page_id="68" body_html="<p>&amp;quot;GIPR Agonist Long Acting&amp;quot; is a biologic entity being studied for the treatment of diabetes.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="GIPR Agonist Long Acting  /Diabetes" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            GIPR Agonist Long Acting  
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Diabetes
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="GIPR Agonist Long Acting II" page_id="68" body_html="<p>&amp;quot;GIPR Agonist Long Acting II&amp;quot; is a biologic entity being studied for the treatment of diabetes.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="GIPR Agonist Long Acting II/Diabetes" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            GIPR Agonist Long Acting II
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Diabetes
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="IDH1/2 Inhibitor   " page_id="68" body_html="<p>&amp;quot;IDH1/2 Inhibitor&amp;quot; is a chemical entity being studied for the treatment of cancer.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 18:22:00" featured_links="" referencetitle="IDH1/2 Inhibitor   /Cancer" clinical_studies="" therapeutic_area_id="205"><div class="smallCard"><div class="card flex-column collapsed Cancer"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            IDH1/2 Inhibitor   
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Cancer
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="KHK Inhibitor II   " page_id="68" body_html="<p>&amp;quot;KHK Inhibitor II&amp;quot; is a chemical entity being studied for the treatment of NASH and diabetes.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="KHK Inhibitor II   /Diabetes" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            KHK Inhibitor II   
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Diabetes
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="KRAS G12C II" page_id="68" body_html="<p>&amp;quot;KRAS G12C II&amp;quot; is a chemical entity being studied for the treatment of cancer.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="KRAS G12C II/Cancer" clinical_studies="" therapeutic_area_id="205"><div class="smallCard"><div class="card flex-column collapsed Cancer"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            KRAS G12C II
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Cancer
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="Lp(a) Inhibitor   " page_id="68" body_html="<p>&amp;quot;Lp(a) Inhibitor&amp;quot; is a chemical entity being studied for the treatment of cardiovascular disease.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="Lp(a) Inhibitor   /CVD" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Lp(a) Inhibitor   
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          CVD
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="Lp(a) siRNA" page_id="68" body_html="<p>Lp(a) siRNA is a small interfering RNA (siRNA) being studied for the treatment of cardiovascular disease.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="Lp(a) siRNA/CVD" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Lp(a) siRNA
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          CVD
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="N3pG 4" page_id="68" body_html="<p>&amp;quot;N3pG 4&amp;quot; is a biologic entity being studied for the treatment of Alzheimer's disease.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 18:43:29" featured_links="" referencetitle="N3pG 4/Alzheimer's Disease " clinical_studies="" therapeutic_area_id="208"><div class="smallCard"><div class="card flex-column collapsed Neurodegeneration"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            N3pG 4
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Alzheimer's Disease 
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="Non- Disclosed" page_id="68" body_html="<p>A  chemical entity for a non disclosed target being studied for the treatment of diabetes.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="Non- Disclosed/Diabetes" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Non- Disclosed
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Diabetes
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="NRG4 Agonist " page_id="68" body_html="<p>&amp;quot;NRG4 Agonist&amp;quot; is a biologic entity being studied for the treatment of heart failure.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="NRG4 Agonist / Heart Failure" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            NRG4 Agonist 
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
           Heart Failure
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="Oxyntomodulin" page_id="68" body_html="<p>&amp;quot;Oxyntomodulin&amp;quot; is a biologic entity being studied for the treatment of diabetes.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="Oxyntomodulin/Diabetes" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Oxyntomodulin
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Diabetes
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="P2X7 Inhibitor  " page_id="68" body_html="<p>&amp;quot;P2X7 Inhibitor&amp;quot; is a chemical entity being studied for the treatment of pain.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="P2X7 Inhibitor  /Pain" clinical_studies="" therapeutic_area_id="209"><div class="smallCard"><div class="card flex-column collapsed Pain"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            P2X7 Inhibitor  
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Pain
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="Peptide YY Analog Agonist" page_id="68" body_html="<p>&amp;quot;Peptide YY Analog Agonist&amp;quot; is a biologic entity being studied for the treatment of diabetes.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="Peptide YY Analog Agonist/Diabetes" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Peptide YY Analog Agonist
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Diabetes
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="Relaxin-LA  " page_id="68" body_html="<p>&amp;quot;Relaxin-LA&amp;quot; is a biologic entity being studied for the treatment of heart failure.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="Relaxin-LA  /Heart Failure" clinical_studies="" therapeutic_area_id="206"><div class="smallCard"><div class="card flex-column collapsed Diabetes"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            Relaxin-LA  
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Heart Failure
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="RET Inhibitor II" page_id="68" body_html="<p>&amp;quot;RET Inhibitor II&amp;quot; is a chemical entity being studied for the treatment of cancer.</p>" created_at="2022-04-22 18:26:51" updated_at="2022-04-26 13:50:48" featured_links="" referencetitle="RET Inhibitor II/Cancer" clinical_studies="" therapeutic_area_id="205"><div class="smallCard"><div class="card flex-column collapsed Cancer"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            RET Inhibitor II
          </a> <div class="icon-wrap"><span class="icon icon-pipeline-plus"></span></div></div> <div class="indication fadeIn smallCard">
          Cancer
        </div></div> <!----></div></div></div><div class="pipeline-card mb-3" type="nme" phase="1" title="RIPK1 Inhibitor  " page_id="68" body_html="<p>&amp;quot;RIPK1 Inhibitor&amp;quot;  is a chemical entity being studied for the treatment of autoimmune diseases.</p>" created_at="2022-04-22 17:23:33" updated_at="2022-04-22 17:23:33" featured_links="" referencetitle="RIPK1 Inhibitor  /Immunology" clinical_studies="" therapeutic_area_id="207"><div class="smallCard"><div class="card flex-column collapsed Immunology"><div class="card-body fadeIn"><div class="card-heading fadeIn simple smallCard"><a href="#" class="lds-link title-link shrinkTitle">
            RIPK1 Inhibitor  
          </a> <div class="icon-wrap"><!----></div></div> <div class="indication fadeIn smallCard">
          Immunology
        </div></div> <!----></div></div></div> <!----></div></div></div></div><div><!----></div></section> <section>
        
        <div class="disclaimer"><p><strong>Pipeline Disclaimer</strong>
<br><br>
The information included on this site reflects Eli Lilly and Company's clinical development pipeline and is not intended for promotional purposes. It includes both new molecular entities as well as select new indications or line extensions of currently approved products that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued or delayed, or to fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of <span class="auto">April 28, 2022</span>. Lilly assumes no duty to update this information. </p>
<p>For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed. </p>
<p>Property of Eli Lilly and Company.</p></div>
        
      </section></div> <div><section class="color"><div class="container"><div id="faqs"><h2 class="align-center">
              Frequently Asked Questions
            </h2>
            
            <div><p>Thank you for visiting Lilly’s clinical development pipeline site. This interactive page is designed to give you a better understanding of the molecules and potential indications Lilly is currently developing for people around the world. Below are responses to some frequently asked questions regarding the site’s information and how it is displayed.</p></div>
            
            <dl id="faq-556" class="lds-accordion"><dt id="faq-556Heading" class="lds-accordion-heading"><button type="button" class="lds-button-base" aria-expanded="false" aria-controls="faq-556Panel"><svg aria-labelledby="lds-icon-679-title" aria-hidden="false" title="Expand accordion" role="img" focusable="false" class="lds-accordion-toggle-icon icon icon-chevron-filled-down"><title id="lds-icon-679-title">
    Expand accordion
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m7.99602499 0c4.41998191 0 8.00401251 3.58001809 8.00401251 8 0 4.4199819-3.5839931 8-8.00401251 8-4.4200194 0-7.99602499-3.5800181-7.99602499-8 0-4.41998191 3.57600559-8 7.99602499-8zm2.71472351 6.36072792-2.35483028 2.38665227c-.1939473.1965682-.51052266.19869287-.70709086.00474557-.00159246-.00157122-.00317435-.00315312-.00474558-.00474557l-2.35483023-2.38665227c-.19394729-.1965682-.51052265-.19869287-.70709086-.00474557-.00159245.00157122-.00317435.00315311-.00474557.00474557l-.23092478.23404539c-.19210905.19470511-.19210905.50764016 0 .70234528l3.29759144 3.34215351c.1939473.1965682.51052266.1986928.70709086.0047456.00159246-.0015713.00317435-.0031532.00474558-.0047456l3.29759148-3.34215351c.192109-.19470512.192109-.50764017 0-.70234528l-.2309248-.23404539c-.1939473-.1965682-.5105227-.19869287-.7070909-.00474557-.0015924.00157122-.0031743.00315311-.0047455.00474557z"></path></svg></svg> <div>
                Abbreviations &amp; Icons
              </div></button></dt> <dd id="faq-556Panel" aria-labledby="faq-556Heading" role="region" class="lds-accordion-panel" style="display: none;"><div class="lds-accordion-panel-body">
              
              <div><div class="row">
    <div class="columns small-12 medium-6">
        <p><strong>β: beta</strong></p>
        <p><strong>NME: new molecular entity</strong></p>
        <p><strong>NILEX: new indication or line extension</strong></p>
    </div>
    <div class="columns small-12 medium-6">
            <p><span class="icon icon-pipeline-check"></span>&nbsp;&nbsp;regulatory approval achieved</p>
            <p><span class="icon icon-pipeline-bookmark"></span>&nbsp;&nbsp;milestone achieved</p>
            <p>
                <span class="icon icon-pipeline-plus"></span>&nbsp;&nbsp;new to pipeline
            </p>
    </div>
</div></div>
              
            </div></dd></dl><dl id="faq-557" class="lds-accordion"><dt id="faq-557Heading" class="lds-accordion-heading"><button type="button" class="lds-button-base" aria-expanded="false" aria-controls="faq-557Panel"><svg aria-labelledby="lds-icon-684-title" aria-hidden="false" title="Expand accordion" role="img" focusable="false" class="lds-accordion-toggle-icon icon icon-chevron-filled-down"><title id="lds-icon-684-title">
    Expand accordion
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m7.99602499 0c4.41998191 0 8.00401251 3.58001809 8.00401251 8 0 4.4199819-3.5839931 8-8.00401251 8-4.4200194 0-7.99602499-3.5800181-7.99602499-8 0-4.41998191 3.57600559-8 7.99602499-8zm2.71472351 6.36072792-2.35483028 2.38665227c-.1939473.1965682-.51052266.19869287-.70709086.00474557-.00159246-.00157122-.00317435-.00315312-.00474558-.00474557l-2.35483023-2.38665227c-.19394729-.1965682-.51052265-.19869287-.70709086-.00474557-.00159245.00157122-.00317435.00315311-.00474557.00474557l-.23092478.23404539c-.19210905.19470511-.19210905.50764016 0 .70234528l3.29759144 3.34215351c.1939473.1965682.51052266.1986928.70709086.0047456.00159246-.0015713.00317435-.0031532.00474558-.0047456l3.29759148-3.34215351c.192109-.19470512.192109-.50764017 0-.70234528l-.2309248-.23404539c-.1939473-.1965682-.5105227-.19869287-.7070909-.00474557-.0015924.00157122-.0031743.00315311-.0047455.00474557z"></path></svg></svg> <div>
                What is the significance of the position of a molecule within a particular phase of development (Phase 1, 2, 3 or Regulatory Review) as compared to other molecules in that same phase?
              </div></button></dt> <dd id="faq-557Panel" aria-labledby="faq-557Heading" role="region" class="lds-accordion-panel" style="display: none;"><div class="lds-accordion-panel-body">
              
              <div><p>Molecules are listed in alphabetical order by phase in development.</p></div>
              
            </div></dd></dl><dl id="faq-558" class="lds-accordion"><dt id="faq-558Heading" class="lds-accordion-heading"><button type="button" class="lds-button-base" aria-expanded="false" aria-controls="faq-558Panel"><svg aria-labelledby="lds-icon-689-title" aria-hidden="false" title="Expand accordion" role="img" focusable="false" class="lds-accordion-toggle-icon icon icon-chevron-filled-down"><title id="lds-icon-689-title">
    Expand accordion
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m7.99602499 0c4.41998191 0 8.00401251 3.58001809 8.00401251 8 0 4.4199819-3.5839931 8-8.00401251 8-4.4200194 0-7.99602499-3.5800181-7.99602499-8 0-4.41998191 3.57600559-8 7.99602499-8zm2.71472351 6.36072792-2.35483028 2.38665227c-.1939473.1965682-.51052266.19869287-.70709086.00474557-.00159246-.00157122-.00317435-.00315312-.00474558-.00474557l-2.35483023-2.38665227c-.19394729-.1965682-.51052265-.19869287-.70709086-.00474557-.00159245.00157122-.00317435.00315311-.00474557.00474557l-.23092478.23404539c-.19210905.19470511-.19210905.50764016 0 .70234528l3.29759144 3.34215351c.1939473.1965682.51052266.1986928.70709086.0047456.00159246-.0015713.00317435-.0031532.00474558-.0047456l3.29759148-3.34215351c.192109-.19470512.192109-.50764017 0-.70234528l-.2309248-.23404539c-.1939473-.1965682-.5105227-.19869287-.7070909-.00474557-.0015924.00157122-.0031743.00315311-.0047455.00474557z"></path></svg></svg> <div>
                What is the significance of the indications listed for each molecule?
              </div></button></dt> <dd id="faq-558Panel" aria-labledby="faq-558Heading" role="region" class="lds-accordion-panel" style="display: none;"><div class="lds-accordion-panel-body">
              
              <div><p>For each molecule, the lead indication, or indication that is furthest along in clinical development, is listed in the molecule’s “box” on the pipeline overview page. If a molecule is being studied for multiple indications, select additional indications will be listed in the molecule’s full description, which is displayed once you click the molecule’s box on the pipeline overview page.</p>
<p>For New Indication or Line Extension (NILEX) molecules, the indication listed is the new indication undergoing clinical study and not the indication which is already approved for marketing by a regulatory agency.</p></div>
              
            </div></dd></dl><dl id="faq-559" class="lds-accordion"><dt id="faq-559Heading" class="lds-accordion-heading"><button type="button" class="lds-button-base" aria-expanded="false" aria-controls="faq-559Panel"><svg aria-labelledby="lds-icon-694-title" aria-hidden="false" title="Expand accordion" role="img" focusable="false" class="lds-accordion-toggle-icon icon icon-chevron-filled-down"><title id="lds-icon-694-title">
    Expand accordion
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m7.99602499 0c4.41998191 0 8.00401251 3.58001809 8.00401251 8 0 4.4199819-3.5839931 8-8.00401251 8-4.4200194 0-7.99602499-3.5800181-7.99602499-8 0-4.41998191 3.57600559-8 7.99602499-8zm2.71472351 6.36072792-2.35483028 2.38665227c-.1939473.1965682-.51052266.19869287-.70709086.00474557-.00159246-.00157122-.00317435-.00315312-.00474558-.00474557l-2.35483023-2.38665227c-.19394729-.1965682-.51052265-.19869287-.70709086-.00474557-.00159245.00157122-.00317435.00315311-.00474557.00474557l-.23092478.23404539c-.19210905.19470511-.19210905.50764016 0 .70234528l3.29759144 3.34215351c.1939473.1965682.51052266.1986928.70709086.0047456.00159246-.0015713.00317435-.0031532.00474558-.0047456l3.29759148-3.34215351c.192109-.19470512.192109-.50764017 0-.70234528l-.2309248-.23404539c-.1939473-.1965682-.5105227-.19869287-.7070909-.00474557-.0015924.00157122-.0031743.00315311-.0047455.00474557z"></path></svg></svg> <div>
                Why are some molecules not identified and simply referred to by therapeutic area (e.g., diabetes)?
              </div></button></dt> <dd id="faq-559Panel" aria-labledby="faq-559Heading" role="region" class="lds-accordion-panel" style="display: none;"><div class="lds-accordion-panel-body">
              
              <div><p>For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed. </p></div>
              
            </div></dd></dl><dl id="faq-560" class="lds-accordion"><dt id="faq-560Heading" class="lds-accordion-heading"><button type="button" class="lds-button-base" aria-expanded="false" aria-controls="faq-560Panel"><svg aria-labelledby="lds-icon-699-title" aria-hidden="false" title="Expand accordion" role="img" focusable="false" class="lds-accordion-toggle-icon icon icon-chevron-filled-down"><title id="lds-icon-699-title">
    Expand accordion
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m7.99602499 0c4.41998191 0 8.00401251 3.58001809 8.00401251 8 0 4.4199819-3.5839931 8-8.00401251 8-4.4200194 0-7.99602499-3.5800181-7.99602499-8 0-4.41998191 3.57600559-8 7.99602499-8zm2.71472351 6.36072792-2.35483028 2.38665227c-.1939473.1965682-.51052266.19869287-.70709086.00474557-.00159246-.00157122-.00317435-.00315312-.00474558-.00474557l-2.35483023-2.38665227c-.19394729-.1965682-.51052265-.19869287-.70709086-.00474557-.00159245.00157122-.00317435.00315311-.00474557.00474557l-.23092478.23404539c-.19210905.19470511-.19210905.50764016 0 .70234528l3.29759144 3.34215351c.1939473.1965682.51052266.1986928.70709086.0047456.00159246-.0015713.00317435-.0031532.00474558-.0047456l3.29759148-3.34215351c.192109-.19470512.192109-.50764017 0-.70234528l-.2309248-.23404539c-.1939473-.1965682-.5105227-.19869287-.7070909-.00474557-.0015924.00157122-.0031743.00315311-.0047455.00474557z"></path></svg></svg> <div>
                How does Lilly determine when a molecule enters a particular phase of clinical development?
              </div></button></dt> <dd id="faq-560Panel" aria-labledby="faq-560Heading" role="region" class="lds-accordion-panel" style="display: none;"><div class="lds-accordion-panel-body">
              
              <div><ul>
<li>Lilly considers Phase 1 clinical development to be underway once the first human dose has been given.</li>

<li>Lilly considers Phase 2 clinical development to be underway once the first efficacy dose has been given.</li>

<li>Lilly considers Phase 3 clinical development to be underway once the first registration dose has been given.</li>

<li>Lilly considers regulatory review to be underway when the first submission has been made.</li></ul></div>
              
            </div></dd></dl><dl id="faq-561" class="lds-accordion"><dt id="faq-561Heading" class="lds-accordion-heading"><button type="button" class="lds-button-base" aria-expanded="false" aria-controls="faq-561Panel"><svg aria-labelledby="lds-icon-704-title" aria-hidden="false" title="Expand accordion" role="img" focusable="false" class="lds-accordion-toggle-icon icon icon-chevron-filled-down"><title id="lds-icon-704-title">
    Expand accordion
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m7.99602499 0c4.41998191 0 8.00401251 3.58001809 8.00401251 8 0 4.4199819-3.5839931 8-8.00401251 8-4.4200194 0-7.99602499-3.5800181-7.99602499-8 0-4.41998191 3.57600559-8 7.99602499-8zm2.71472351 6.36072792-2.35483028 2.38665227c-.1939473.1965682-.51052266.19869287-.70709086.00474557-.00159246-.00157122-.00317435-.00315312-.00474558-.00474557l-2.35483023-2.38665227c-.19394729-.1965682-.51052265-.19869287-.70709086-.00474557-.00159245.00157122-.00317435.00315311-.00474557.00474557l-.23092478.23404539c-.19210905.19470511-.19210905.50764016 0 .70234528l3.29759144 3.34215351c.1939473.1965682.51052266.1986928.70709086.0047456.00159246-.0015713.00317435-.0031532.00474558-.0047456l3.29759148-3.34215351c.192109-.19470512.192109-.50764017 0-.70234528l-.2309248-.23404539c-.1939473-.1965682-.5105227-.19869287-.7070909-.00474557-.0015924.00157122-.0031743.00315311-.0047455.00474557z"></path></svg></svg> <div>
                How does Lilly define First Human Dose?
              </div></button></dt> <dd id="faq-561Panel" aria-labledby="faq-561Heading" role="region" class="lds-accordion-panel" style="display: none;"><div class="lds-accordion-panel-body">
              
              <div><p>Lilly defines First Human Dose as the date of the first dose administered in the initial clinical study of the molecule given to healthy volunteers. This is typically a single-dose pharmacokinetic safety study (study of how the investigational medicine acts on the body over a period of time, from a safety perspective). This dose may be active LY, placebo or comparator. </p>
<p>In some cases, such as oncology and autoimmunity, the First Human Dose is given to patients with the disease the molecule is being studied to treat.</p></div>
              
            </div></dd></dl><dl id="faq-562" class="lds-accordion"><dt id="faq-562Heading" class="lds-accordion-heading"><button type="button" class="lds-button-base" aria-expanded="false" aria-controls="faq-562Panel"><svg aria-labelledby="lds-icon-709-title" aria-hidden="false" title="Expand accordion" role="img" focusable="false" class="lds-accordion-toggle-icon icon icon-chevron-filled-down"><title id="lds-icon-709-title">
    Expand accordion
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m7.99602499 0c4.41998191 0 8.00401251 3.58001809 8.00401251 8 0 4.4199819-3.5839931 8-8.00401251 8-4.4200194 0-7.99602499-3.5800181-7.99602499-8 0-4.41998191 3.57600559-8 7.99602499-8zm2.71472351 6.36072792-2.35483028 2.38665227c-.1939473.1965682-.51052266.19869287-.70709086.00474557-.00159246-.00157122-.00317435-.00315312-.00474558-.00474557l-2.35483023-2.38665227c-.19394729-.1965682-.51052265-.19869287-.70709086-.00474557-.00159245.00157122-.00317435.00315311-.00474557.00474557l-.23092478.23404539c-.19210905.19470511-.19210905.50764016 0 .70234528l3.29759144 3.34215351c.1939473.1965682.51052266.1986928.70709086.0047456.00159246-.0015713.00317435-.0031532.00474558-.0047456l3.29759148-3.34215351c.192109-.19470512.192109-.50764017 0-.70234528l-.2309248-.23404539c-.1939473-.1965682-.5105227-.19869287-.7070909-.00474557-.0015924.00157122-.0031743.00315311-.0047455.00474557z"></path></svg></svg> <div>
                How does Lilly define First Efficacy Dose?
              </div></button></dt> <dd id="faq-562Panel" aria-labledby="faq-562Heading" role="region" class="lds-accordion-panel" style="display: none;"><div class="lds-accordion-panel-body">
              
              <div><p>Lilly defines First Efficacy Dose as the date of the first dose administered to patients with the disease the molecule is being studied to treat, in a clinical study in which efficacy is a primary endpoint. The outcome of the clinical study should provide meaningful data on efficacy that drives a decision on whether to pursue development of the targeted indication for the molecule. This dose may be active LY, placebo or comparator.</p></div>
              
            </div></dd></dl><dl id="faq-563" class="lds-accordion"><dt id="faq-563Heading" class="lds-accordion-heading"><button type="button" class="lds-button-base" aria-expanded="false" aria-controls="faq-563Panel"><svg aria-labelledby="lds-icon-714-title" aria-hidden="false" title="Expand accordion" role="img" focusable="false" class="lds-accordion-toggle-icon icon icon-chevron-filled-down"><title id="lds-icon-714-title">
    Expand accordion
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m7.99602499 0c4.41998191 0 8.00401251 3.58001809 8.00401251 8 0 4.4199819-3.5839931 8-8.00401251 8-4.4200194 0-7.99602499-3.5800181-7.99602499-8 0-4.41998191 3.57600559-8 7.99602499-8zm2.71472351 6.36072792-2.35483028 2.38665227c-.1939473.1965682-.51052266.19869287-.70709086.00474557-.00159246-.00157122-.00317435-.00315312-.00474558-.00474557l-2.35483023-2.38665227c-.19394729-.1965682-.51052265-.19869287-.70709086-.00474557-.00159245.00157122-.00317435.00315311-.00474557.00474557l-.23092478.23404539c-.19210905.19470511-.19210905.50764016 0 .70234528l3.29759144 3.34215351c.1939473.1965682.51052266.1986928.70709086.0047456.00159246-.0015713.00317435-.0031532.00474558-.0047456l3.29759148-3.34215351c.192109-.19470512.192109-.50764017 0-.70234528l-.2309248-.23404539c-.1939473-.1965682-.5105227-.19869287-.7070909-.00474557-.0015924.00157122-.0031743.00315311-.0047455.00474557z"></path></svg></svg> <div>
                How does Lilly define First Registration Dose?
              </div></button></dt> <dd id="faq-563Panel" aria-labledby="faq-563Heading" role="region" class="lds-accordion-panel" style="display: none;"><div class="lds-accordion-panel-body">
              
              <div><p>Lilly defines First Registration Dose as the date of the first dose administered in the first large-scale pivotal study designed or intended to support registration in a major market (US, EU, China or Japan). This may occur before all Phase 2 studies have been completed. This dose may be active LY, placebo or comparator.</p></div>
              
            </div></dd></dl><dl id="faq-564" class="lds-accordion"><dt id="faq-564Heading" class="lds-accordion-heading"><button type="button" class="lds-button-base" aria-expanded="false" aria-controls="faq-564Panel"><svg aria-labelledby="lds-icon-719-title" aria-hidden="false" title="Expand accordion" role="img" focusable="false" class="lds-accordion-toggle-icon icon icon-chevron-filled-down"><title id="lds-icon-719-title">
    Expand accordion
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m7.99602499 0c4.41998191 0 8.00401251 3.58001809 8.00401251 8 0 4.4199819-3.5839931 8-8.00401251 8-4.4200194 0-7.99602499-3.5800181-7.99602499-8 0-4.41998191 3.57600559-8 7.99602499-8zm2.71472351 6.36072792-2.35483028 2.38665227c-.1939473.1965682-.51052266.19869287-.70709086.00474557-.00159246-.00157122-.00317435-.00315312-.00474558-.00474557l-2.35483023-2.38665227c-.19394729-.1965682-.51052265-.19869287-.70709086-.00474557-.00159245.00157122-.00317435.00315311-.00474557.00474557l-.23092478.23404539c-.19210905.19470511-.19210905.50764016 0 .70234528l3.29759144 3.34215351c.1939473.1965682.51052266.1986928.70709086.0047456.00159246-.0015713.00317435-.0031532.00474558-.0047456l3.29759148-3.34215351c.192109-.19470512.192109-.50764017 0-.70234528l-.2309248-.23404539c-.1939473-.1965682-.5105227-.19869287-.7070909-.00474557-.0015924.00157122-.0031743.00315311-.0047455.00474557z"></path></svg></svg> <div>
                How does Lilly define First Submission?
              </div></button></dt> <dd id="faq-564Panel" aria-labledby="faq-564Heading" role="region" class="lds-accordion-panel" style="display: none;"><div class="lds-accordion-panel-body">
              
              <div><p>Lilly defines First Submission as the initial submission of a regulatory dossier to a health authority to obtain regulatory approval for Lilly to market any indication or product form of a potential new medicine in one of the major markets (US, EU, China or Japan).</p></div>
              
            </div></dd></dl><dl id="faq-565" class="lds-accordion"><dt id="faq-565Heading" class="lds-accordion-heading"><button type="button" class="lds-button-base" aria-expanded="false" aria-controls="faq-565Panel"><svg aria-labelledby="lds-icon-724-title" aria-hidden="false" title="Expand accordion" role="img" focusable="false" class="lds-accordion-toggle-icon icon icon-chevron-filled-down"><title id="lds-icon-724-title">
    Expand accordion
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m7.99602499 0c4.41998191 0 8.00401251 3.58001809 8.00401251 8 0 4.4199819-3.5839931 8-8.00401251 8-4.4200194 0-7.99602499-3.5800181-7.99602499-8 0-4.41998191 3.57600559-8 7.99602499-8zm2.71472351 6.36072792-2.35483028 2.38665227c-.1939473.1965682-.51052266.19869287-.70709086.00474557-.00159246-.00157122-.00317435-.00315312-.00474558-.00474557l-2.35483023-2.38665227c-.19394729-.1965682-.51052265-.19869287-.70709086-.00474557-.00159245.00157122-.00317435.00315311-.00474557.00474557l-.23092478.23404539c-.19210905.19470511-.19210905.50764016 0 .70234528l3.29759144 3.34215351c.1939473.1965682.51052266.1986928.70709086.0047456.00159246-.0015713.00317435-.0031532.00474558-.0047456l3.29759148-3.34215351c.192109-.19470512.192109-.50764017 0-.70234528l-.2309248-.23404539c-.1939473-.1965682-.5105227-.19869287-.7070909-.00474557-.0015924.00157122-.0031743.00315311-.0047455.00474557z"></path></svg></svg> <div>
                Which molecules include links to press releases and what are the criteria for press release inclusion?
              </div></button></dt> <dd id="faq-565Panel" aria-labledby="faq-565Heading" role="region" class="lds-accordion-panel" style="display: none;"><div class="lds-accordion-panel-body">
              
              <div><p>For molecules in Phase 3 development and under regulatory review, Lilly’s interactive pipeline website includes links to press releases issued January 1, 2010, through the pipeline date listed at the top of the site.</p>
<p>For announcements related to molecules in other phases (Phase 1, Phase 2, NILEX), as well as broader pipeline announcements, please visit the press release archives in the <a href="https://www.lilly.com/newsroom">Lilly.com Newsroom</a>.</p></div>
              
            </div></dd></dl><dl id="faq-566" class="lds-accordion"><dt id="faq-566Heading" class="lds-accordion-heading"><button type="button" class="lds-button-base" aria-expanded="false" aria-controls="faq-566Panel"><svg aria-labelledby="lds-icon-729-title" aria-hidden="false" title="Expand accordion" role="img" focusable="false" class="lds-accordion-toggle-icon icon icon-chevron-filled-down"><title id="lds-icon-729-title">
    Expand accordion
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m7.99602499 0c4.41998191 0 8.00401251 3.58001809 8.00401251 8 0 4.4199819-3.5839931 8-8.00401251 8-4.4200194 0-7.99602499-3.5800181-7.99602499-8 0-4.41998191 3.57600559-8 7.99602499-8zm2.71472351 6.36072792-2.35483028 2.38665227c-.1939473.1965682-.51052266.19869287-.70709086.00474557-.00159246-.00157122-.00317435-.00315312-.00474558-.00474557l-2.35483023-2.38665227c-.19394729-.1965682-.51052265-.19869287-.70709086-.00474557-.00159245.00157122-.00317435.00315311-.00474557.00474557l-.23092478.23404539c-.19210905.19470511-.19210905.50764016 0 .70234528l3.29759144 3.34215351c.1939473.1965682.51052266.1986928.70709086.0047456.00159246-.0015713.00317435-.0031532.00474558-.0047456l3.29759148-3.34215351c.192109-.19470512.192109-.50764017 0-.70234528l-.2309248-.23404539c-.1939473-.1965682-.5105227-.19869287-.7070909-.00474557-.0015924.00157122-.0031743.00315311-.0047455.00474557z"></path></svg></svg> <div>
                Why are some molecules listed on the pipeline website in Phase 2 clinical development, but noted as Phase 1 on ClinicalTrials.gov?
              </div></button></dt> <dd id="faq-566Panel" aria-labledby="faq-566Heading" role="region" class="lds-accordion-panel" style="display: none;"><div class="lds-accordion-panel-body">
              
              <div><p>Lilly defines the start of Phase 2 as the first dose in a clinical study for the purpose of evaluating efficacy, whether that occurs in a Phase 1 cohort or a separate Phase 2 study. Some oncology pipeline molecules are considered by Lilly to be in Phase 2 clinical development, although clinicaltrials.gov lists them as Phase 1 based on a Phase 1 study.</p></div>
              
            </div></dd></dl><dl id="faq-567" class="lds-accordion"><dt id="faq-567Heading" class="lds-accordion-heading"><button type="button" class="lds-button-base" aria-expanded="false" aria-controls="faq-567Panel"><svg aria-labelledby="lds-icon-734-title" aria-hidden="false" title="Expand accordion" role="img" focusable="false" class="lds-accordion-toggle-icon icon icon-chevron-filled-down"><title id="lds-icon-734-title">
    Expand accordion
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m7.99602499 0c4.41998191 0 8.00401251 3.58001809 8.00401251 8 0 4.4199819-3.5839931 8-8.00401251 8-4.4200194 0-7.99602499-3.5800181-7.99602499-8 0-4.41998191 3.57600559-8 7.99602499-8zm2.71472351 6.36072792-2.35483028 2.38665227c-.1939473.1965682-.51052266.19869287-.70709086.00474557-.00159246-.00157122-.00317435-.00315312-.00474558-.00474557l-2.35483023-2.38665227c-.19394729-.1965682-.51052265-.19869287-.70709086-.00474557-.00159245.00157122-.00317435.00315311-.00474557.00474557l-.23092478.23404539c-.19210905.19470511-.19210905.50764016 0 .70234528l3.29759144 3.34215351c.1939473.1965682.51052266.1986928.70709086.0047456.00159246-.0015713.00317435-.0031532.00474558-.0047456l3.29759148-3.34215351c.192109-.19470512.192109-.50764017 0-.70234528l-.2309248-.23404539c-.1939473-.1965682-.5105227-.19869287-.7070909-.00474557-.0015924.00157122-.0031743.00315311-.0047455.00474557z"></path></svg></svg> <div>
                Why are some molecules in the pipeline followed by a 1 or 2?
              </div></button></dt> <dd id="faq-567Panel" aria-labledby="faq-567Heading" role="region" class="lds-accordion-panel" style="display: none;"><div class="lds-accordion-panel-body">
              
              <div><p>In some cases, the pipeline includes two or more molecules that act on the same disease target. To distinguish these molecules until a nonproprietary name is granted, they are numbered on Lilly’s pipeline website. </p></div>
              
            </div></dd></dl><dl id="faq-568" class="lds-accordion"><dt id="faq-568Heading" class="lds-accordion-heading"><button type="button" class="lds-button-base" aria-expanded="false" aria-controls="faq-568Panel"><svg aria-labelledby="lds-icon-739-title" aria-hidden="false" title="Expand accordion" role="img" focusable="false" class="lds-accordion-toggle-icon icon icon-chevron-filled-down"><title id="lds-icon-739-title">
    Expand accordion
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m7.99602499 0c4.41998191 0 8.00401251 3.58001809 8.00401251 8 0 4.4199819-3.5839931 8-8.00401251 8-4.4200194 0-7.99602499-3.5800181-7.99602499-8 0-4.41998191 3.57600559-8 7.99602499-8zm2.71472351 6.36072792-2.35483028 2.38665227c-.1939473.1965682-.51052266.19869287-.70709086.00474557-.00159246-.00157122-.00317435-.00315312-.00474558-.00474557l-2.35483023-2.38665227c-.19394729-.1965682-.51052265-.19869287-.70709086-.00474557-.00159245.00157122-.00317435.00315311-.00474557.00474557l-.23092478.23404539c-.19210905.19470511-.19210905.50764016 0 .70234528l3.29759144 3.34215351c.1939473.1965682.51052266.1986928.70709086.0047456.00159246-.0015713.00317435-.0031532.00474558-.0047456l3.29759148-3.34215351c.192109-.19470512.192109-.50764017 0-.70234528l-.2309248-.23404539c-.1939473-.1965682-.5105227-.19869287-.7070909-.00474557-.0015924.00157122-.0031743.00315311-.0047455.00474557z"></path></svg></svg> <div>
                What is a commercial collaboration?
              </div></button></dt> <dd id="faq-568Panel" aria-labledby="faq-568Heading" role="region" class="lds-accordion-panel" style="display: none;"><div class="lds-accordion-panel-body">
              
              <div><p>Some pipeline molecules will be commercialized (sold and marketed) with other companies after the medicine is approved. This is referred to as a commercial collaboration.</p></div>
              
            </div></dd></dl><dl id="faq-569" class="lds-accordion"><dt id="faq-569Heading" class="lds-accordion-heading"><button type="button" class="lds-button-base" aria-expanded="false" aria-controls="faq-569Panel"><svg aria-labelledby="lds-icon-744-title" aria-hidden="false" title="Expand accordion" role="img" focusable="false" class="lds-accordion-toggle-icon icon icon-chevron-filled-down"><title id="lds-icon-744-title">
    Expand accordion
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m7.99602499 0c4.41998191 0 8.00401251 3.58001809 8.00401251 8 0 4.4199819-3.5839931 8-8.00401251 8-4.4200194 0-7.99602499-3.5800181-7.99602499-8 0-4.41998191 3.57600559-8 7.99602499-8zm2.71472351 6.36072792-2.35483028 2.38665227c-.1939473.1965682-.51052266.19869287-.70709086.00474557-.00159246-.00157122-.00317435-.00315312-.00474558-.00474557l-2.35483023-2.38665227c-.19394729-.1965682-.51052265-.19869287-.70709086-.00474557-.00159245.00157122-.00317435.00315311-.00474557.00474557l-.23092478.23404539c-.19210905.19470511-.19210905.50764016 0 .70234528l3.29759144 3.34215351c.1939473.1965682.51052266.1986928.70709086.0047456.00159246-.0015713.00317435-.0031532.00474558-.0047456l3.29759148-3.34215351c.192109-.19470512.192109-.50764017 0-.70234528l-.2309248-.23404539c-.1939473-.1965682-.5105227-.19869287-.7070909-.00474557-.0015924.00157122-.0031743.00315311-.0047455.00474557z"></path></svg></svg> <div>
                What is the difference between a small and large molecule?
              </div></button></dt> <dd id="faq-569Panel" aria-labledby="faq-569Heading" role="region" class="lds-accordion-panel" style="display: none;"><div class="lds-accordion-panel-body">
              
              <div><p>A new small molecule, or chemical entity, is a molecule that is chemically derived, or synthesized, through chemical processes, and are typically administered orally. A new large molecule, or biologic entity, is comprised of biological products such as proteins, peptides or antibodies, and are typically administered intravenously or subcutaneously.</p></div>
              
            </div></dd></dl><dl id="faq-570" class="lds-accordion"><dt id="faq-570Heading" class="lds-accordion-heading"><button type="button" class="lds-button-base" aria-expanded="false" aria-controls="faq-570Panel"><svg aria-labelledby="lds-icon-749-title" aria-hidden="false" title="Expand accordion" role="img" focusable="false" class="lds-accordion-toggle-icon icon icon-chevron-filled-down"><title id="lds-icon-749-title">
    Expand accordion
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m7.99602499 0c4.41998191 0 8.00401251 3.58001809 8.00401251 8 0 4.4199819-3.5839931 8-8.00401251 8-4.4200194 0-7.99602499-3.5800181-7.99602499-8 0-4.41998191 3.57600559-8 7.99602499-8zm2.71472351 6.36072792-2.35483028 2.38665227c-.1939473.1965682-.51052266.19869287-.70709086.00474557-.00159246-.00157122-.00317435-.00315312-.00474558-.00474557l-2.35483023-2.38665227c-.19394729-.1965682-.51052265-.19869287-.70709086-.00474557-.00159245.00157122-.00317435.00315311-.00474557.00474557l-.23092478.23404539c-.19210905.19470511-.19210905.50764016 0 .70234528l3.29759144 3.34215351c.1939473.1965682.51052266.1986928.70709086.0047456.00159246-.0015713.00317435-.0031532.00474558-.0047456l3.29759148-3.34215351c.192109-.19470512.192109-.50764017 0-.70234528l-.2309248-.23404539c-.1939473-.1965682-.5105227-.19869287-.7070909-.00474557-.0015924.00157122-.0031743.00315311-.0047455.00474557z"></path></svg></svg> <div>
                When are molecules listed as “milestone achieved”?
              </div></button></dt> <dd id="faq-570Panel" aria-labledby="faq-570Heading" role="region" class="lds-accordion-panel" style="display: none;"><div class="lds-accordion-panel-body">
              
              <div><p>Molecules are listed as “milestone achieved” during the quarter after the milestone was achieved. For Q1 2021, milestone achievement occurred April 23, 2021 - July 30, 2021.</p></div>
              
            </div></dd></dl></div></div></section></div></div></div></div> <!----></div> <!----> <!----> <footer id="lds-footer" class="lds-footer"><div class="wrapper"><div class="row"><div class="col-12 col-md-9 lds-footer-main-links"><div class="row"><div class="col-12 col-md-auto"><a href="/impact/empowering-a-diverse-workforce" class="lds-link" target="_self">
              Diversity
            </a></div><div class="col-12 col-md-auto"><a href="/contact-us" class="lds-link" target="_self">
              Contact
            </a></div><div class="col-12 col-md-auto"><a href="/suppliers" class="lds-link" target="_self">
              Suppliers
            </a></div><div class="col-12 col-md-auto"><a href="/login" class="lds-link" target="_self">
              Login
            </a></div><div class="col-12 col-md-auto d-md-none"><div><a href="/terms-of-use" class="lds-link lds-footer-main-links-global" target="_self">
                  Terms of Use
                </a></div><div><a href="/privacy" class="lds-link lds-footer-main-links-global" target="_self">
                  Privacy Statement
                </a></div><div><a href="https://www.lillyhub.com/ux/lillyusa/english/accessibility.html" class="lds-link lds-footer-main-links-global" target="_blank">
                  Accessibility Statement
                </a></div><div><a href="/lilly-sitemap" class="lds-link lds-footer-main-links-global" target="_self">
                  Sitemap
                </a></div></div></div></div> <div class="col-12 col-md-3 lds-footer-support"><div><p><strong>To speak to customer support:</strong><br>
        Call <span class="text-nowrap">(800) 545-5979</span></p></div></div></div> <div class="lds-footer-meta"><div>This site is intended for U.S. residents ages 18 and older.<br><a href="https://e.lilly/32DJeOl" target="_blank" class="lds-link">Copyright © 2022 Lilly. All rights reserved.</a></div></div> <div class="row"><div class="col-12 col-md-auto order-md-2 ml-auto"><div class="lds-footer-social-icons"><div><a href="https://twitter.com/LillyPad" class="lds-link" target="_blank"><svg aria-labelledby="lds-icon-56-title" aria-hidden="false" title="Twitter" role="img" focusable="false" class="icon icon-twitter"><title id="lds-icon-56-title">
    Twitter
  </title> <!----> <svg viewBox="0 0 16 13" xmlns="http://www.w3.org/2000/svg"><path d="m.51592258 12.0406027c1.74189865.2057892 3.48057356-.2774146 4.85980053-1.3587435-1.43617986-.0267259-2.6488465-.97442539-3.06578461-2.27918259.51418785.09888574 1.01977904.07002179 1.48184962-.05558982-1.57909936-.31750339-2.66818899-1.73931993-2.63326505-3.25948769.44326539.24587805.94939387.3939394 1.48775983.41050944-1.46250713-.97656346-1.8762215-2.90617162-1.016018-4.38143991 1.61885893 1.9857325 4.03774472 3.29209326 6.76557306 3.42946425-.47872662-2.05361622 1.07941838-4.03026191 3.19795834-4.03026191.9440209 0 1.7972396.39821553 2.3957822 1.03642942.7479096-.14699231 1.4501494-.42013075 2.0841533-.79643107-.2450049.76649809-.7656402 1.40952264-1.4426274 1.81522142.6635549-.07857408 1.2964841-.25549937 1.8848182-.5163439-.4395044.65852555-.9961382 1.23633896-1.6376641 1.6986966.2073944 4.61609308-3.2355687 9.76242756-9.33060215 9.76242756-1.85311797 0-3.57889788-.5441388-5.03173377-1.4752683" fill-rule="evenodd"></path></svg></svg></a> <a href="https://www.facebook.com/elilillyandco" class="lds-link" target="_blank"><svg aria-labelledby="lds-icon-59-title" aria-hidden="false" title="Facebook" role="img" focusable="false" class="icon icon-facebook"><title id="lds-icon-59-title">
    Facebook
  </title> <!----> <svg viewBox="0 0 9 16" xmlns="http://www.w3.org/2000/svg"><path d="m8.67416189.00332907-2.15869076-.00332907c-2.42521503 0-3.99249553 1.5455198-3.99249553 3.93762159v1.81550721h-2.170467c-.18755412 0-.33943313.14614609-.33943313.32641512v2.63046305c0 .18026903.15205219.32624866.33943313.32624866h2.170467v6.63749567c0 .1802691.15187901.3262487.33943313.3262487h2.83184206c.18755412 0 .33943312-.1461461.33943312-.3262487v-6.63749567h2.53778214c.18755412 0 .33943312-.14597963.33943312-.32624866l.00103909-2.63046305c0-.08655577-.0358483-.16944956-.09940542-.23070441s-.1501472-.09571071-.24020089-.09571071h-2.53864804v-1.53902812c0-.7397189.1833978-1.11523776 1.18593777-1.11523776l1.45419385-.00049936c.18738094 0 .33925994-.14614609.33925994-.32624867v-2.44253716c0-.17993612-.15170582-.32591576-.33891358-.32624866z"></path></svg></svg></a> <a href="https://www.instagram.com/elilillyco/" class="lds-link" target="_blank"><svg aria-labelledby="lds-icon-62-title" aria-hidden="false" title="Instagram" role="img" focusable="false" class="icon icon-instagram"><title id="lds-icon-62-title">
    Instagram
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m11 0h-6c-2.761 0-5 2.239-5 5v6c0 2.761 2.239 5 5 5h6c2.761 0 5-2.239 5-5v-6c0-2.761-2.239-5-5-5zm3.5 11c0 1.93-1.57 3.5-3.5 3.5h-6c-1.93 0-3.5-1.57-3.5-3.5v-6c0-1.93 1.57-3.5 3.5-3.5h6c1.93 0 3.5 1.57 3.5 3.5zm-6.5-7c-2.209 0-4 1.791-4 4s1.791 4 4 4 4-1.791 4-4-1.791-4-4-4zm0 6.5c-1.378 0-2.5-1.122-2.5-2.5 0-1.379 1.122-2.5 2.5-2.5s2.5 1.121 2.5 2.5c0 1.378-1.122 2.5-2.5 2.5zm4.3-6.267c.2943678 0 .533-.23863223.533-.533s-.2386322-.533-.533-.533-.533.23863223-.533.533.2386322.533.533.533z"></path></svg></svg></a> <a href="https://www.linkedin.com/company/eli-lilly-and-company/" class="lds-link" target="_blank"><svg aria-labelledby="lds-icon-65-title" aria-hidden="false" title="LinkedIn" role="img" focusable="false" class="icon icon-linkedin"><title id="lds-icon-65-title">
    LinkedIn
  </title> <!----> <svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg"><path d="m16 9.82727973v6.18916327h-3.4306819v-5.7775259c0-1.45258443-.4946577-2.43981378-1.7360032-2.43981378-.94932925 0-1.50933678.66838985-1.7593258 1.31163672-.09001077.23164451-.11734861.55605189-.11734861.87629211v6.02867545h-3.42730229s.04600922-9.78152668 0-10.79456435h3.42800498v1.53000939c-.00465112.01257149-.01465603.02300687-.01934061.03697908h.01934061v-.03697908c.45798417-.73534439 1.26931912-1.78329507 3.09131782-1.78329507 2.261345.00003502 3.951339 1.5426159 3.951339 4.85942216zm-14.05934771-9.81083678c-1.17264961 0-1.94065229.8051354-1.94065229 1.86702327 0 1.03327811.74534941 1.86562254 1.89665074 1.86562254h.02067905c1.198649 0 1.94132151-.83234443 1.94132151-1.86562254-.02332249-1.06188787-.74263904-1.86702327-1.91799901-1.86702327zm-1.73596981 15.99996495h3.42867421v-10.79592999h-3.42867421z"></path></svg></svg></a> <a href="https://www.youtube.com/user/EliLillyandCompany" class="lds-link" target="_blank"><svg aria-labelledby="lds-icon-68-title" aria-hidden="false" title="YouTube" role="img" focusable="false" class="icon icon-youtube"><title id="lds-icon-68-title">
    YouTube
  </title> <!----> <svg viewBox="0 0 13 16" xmlns="http://www.w3.org/2000/svg"><g><path d="m12.7107922 8.07156044c-.1581948-.71578022-.7204026-1.24378022-1.3970779-1.32237363-1.60203898-.18637362-3.22433768-.18725274-4.83870131-.18637362-1.61503896-.00087912-3.237 0-4.83954546.18637362-.67633766.07876923-1.23820779.60676923-1.39623376 1.32237363-.22522078 1.01925275-.22792208 2.13186816-.22792208 3.18136266s0 2.161934.22522078 3.1811868c.15802597.7156044.7198961 1.2436044 1.39657143 1.3223736 1.60220779.1865495 3.22416883.1872528 4.83903896.1865495 1.61503896.0008791 3.23666233 0 4.83937664-.1865495.6763376-.0787692 1.2385454-.6067692 1.3965714-1.3223736.225052-1.0192528.2262338-2.1316923.2262338-3.1811868-.0001689-1.0496704.0015195-2.16210991-.2235325-3.18136266zm-9.0133896.78997802h-.93532468v5.17591204h-.86880519v-5.17591204h-.91827273v-.84782417h2.7224026zm2.35975324 5.17608794h-.78151948v-.4896704c-.31048052.3706374-.60525974.5513847-.89244155.5513847-.25172728 0-.42494806-.1061978-.50311689-.3335385-.04254545-.1357363-.06888311-.3505934-.06888311-.6674286v-3.54918679h.78084415v3.30461539c0 .1905934 0 .2895824.00709091.3163077.01874026.1262417.078.1902417.18267532.1902417.15667533 0 .32044156-.1257142.49366234-.3808351v-3.43032969h.78151948zm2.96687013-1.3471649c0 .4151209-.02684415.7141978-.07901298.9044396-.10433767.3338901-.31318182.5044396-.62383117.5044396-.27789611 0-.546-.1607033-.80718182-.4965275v.434989h-.78084416v-6.02408791h.78084416v1.9672967c.25223377-.32334066.52-.48685714.80718182-.48685714.31064935 0 .51966234.17037362.62383117.50637365.05250649.1805714.07901298.4773626.07901298.9023296zm2.94728573-.7488351h-1.5618572v.7956044c0 .4154725.1305065.622945.3989481.622945.1922987 0 .3042338-.1088351.3488052-.3261538.0072597-.0441319.0175584-.2248791.0175584-.551033h.7967143v.1186813c0 .2621539-.0096234.4427253-.0167143.5239561-.0261688.1800439-.0876233.3433846-.1823376.4872088-.2162728.325978-.5367143.4866813-.9446104.4866813-.4085714 0-.7195585-.1531429-.94528573-.4596044-.16562338-.2247033-.25071429-.5784616-.25071429-1.0554725v-1.572044c0-.4798242.07546753-.8307692.24142857-1.05758241.22555845-.30716484.53637665-.46013187.93532465-.46013187.3918572 0 .7025065.15296703.9213117.46013187.1635974.22681321.2417663.57775821.2417663 1.05758241v.9292308z"></path><path d="m10.8014805 10.2264615c-.261013 0-.3918571.2076484-.3918571.6225934v.4152967h.7808441v-.4152967c-.0001688-.414945-.1306753-.6225934-.388987-.6225934z"></path><path d="m7.90332468 10.2264615c-.12864936 0-.25898702.0632967-.38949351.1978022v2.7356484c.13033766.1360879.26084415.2004395.38949351.2004395.22522077 0 .33968831-.2004395.33968831-.6057142v-1.9157803c0-.4047472-.11446754-.6123956-.33968831-.6123956z"></path><path d="m8.33958442 6.1490989c.28785714 0 .58736363-.18215385.90155844-.55701099v.49476923h.78928574v-4.53608791h-.78928574v3.4669011c-.17490909.25740659-.3407013.3847033-.49855844.3847033-.10568832 0-.16781819-.06505495-.18503897-.19252748-.00962337-.0269011-.00962337-.12694505-.00962337-.31947252v-3.3396044h-.78675325v3.58681319c0 .32035165.02633766.53714285.06989611.67446154.07935064.22980219.25442857.33705494.50851948.33705494z"></path><path d="m2.84497403 3.62162637v2.46523077h.87522078v-2.46523077l1.05283116-3.62162637h-.88501298l-.59715585 2.39032967-.6212987-2.39032967h-.92097402c.18453246.56421978.3764935 1.13125275.56102597 1.696.28076623.84887912.45601299 1.48887912.53536364 1.92562637z"></path><path d="m5.94606494 6.1490989c.39540259 0 .70267532-.1549011.92063636-.46435165.16562338-.22698901.24497402-.58461538.24497402-1.06672527v-1.58839561c0-.48492307-.07918181-.83938461-.24497402-1.06848351-.21796104-.31032967-.52506494-.46523077-.92063636-.46523077-.39337663 0-.70048052.1549011-.91894806.46523077-.16764935.2290989-.247.58356044-.247 1.06848351v1.58839561c0 .48210989.07935065.83973626.247 1.06672527.2182987.30945055.52557143.46435165.91894806.46435165zm-.37666234-3.28421978c0-.41969231.12223376-.62892308.37666234-.62892308.25442857 0 .37632467.20905495.37632467.62892308v1.90804396c0 .4196923-.1218961.62962637-.37632467.62962637-.25442858 0-.37666234-.20993407-.37666234-.62962637z"></path></g></svg></svg></a></div></div> <div class="lds-footer-global-links d-none d-md-block"><a href="/terms-of-use" class="lds-link" target="_self">
            Terms of Use
          </a><a href="/privacy" class="lds-link" target="_self">
            Privacy Statement
          </a><a href="https://www.lillyhub.com/ux/lillyusa/english/accessibility.html" class="lds-link" target="_blank">
            Accessibility Statement
          </a><a href="/lilly-sitemap" class="lds-link" target="_self">
            Sitemap
          </a></div></div> <div class="col-12 col-md-auto order-md-1 lds-footer-logo"><a href="http://lilly.com" class="lds-link lds-footer-logo-img lds-logo-lilly logo-md logo-red logo-disable-padding-right logo-disable-padding-bottom logo-disable-padding-left" aria-label="Visit Lilly.com"><svg viewBox="0 0 631 344" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><title>Lilly</title> <path id="Lilly" d="M435.528098,200.793973 C439.182374,198.191364 443.134091,195.153215 446.820236,192.231919 C475.215236,169.509545 496.917811,144.609478 501.198838,130.831582 C501.358182,130.385421 501.740606,129.121296 501.740606,128.101498 C501.740606,126.67803 501.060741,125.679478 499.754125,125.679478 C486.741077,125.679478 444.886869,167.331852 434.763249,201.048923 L434.763249,201.18702 L435.528098,200.793973 Z M330.648249,196.003047 C370.19729,166.131465 411.732811,122.630707 416.162559,104.77362 C416.311279,104.18936 416.449377,103.615724 416.428131,103.073956 C416.375017,101.905438 415.737643,100.853771 414.250438,100.853771 C401.736667,100.853771 343.767525,154.297559 330.648249,196.003047 Z M87.830101,222.262845 C77.3877946,215.01803 61.2409933,208.686785 46.8257239,208.686785 C32.8353704,208.686785 23.8802694,214.178822 23.8802694,221.104949 C23.8802694,229.082744 34.7474916,232.567054 46.9000842,232.567054 C61.6446633,232.567054 75.0188889,228.583468 87.830101,222.262845 Z M208.984226,128.54766 C237.326111,119.454461 264.223283,100.450101 284.27931,80.606532 C302.826886,62.2395455 317.667071,40.4307407 317.667071,29.6378788 C317.667071,27.173367 315.90367,25.6861616 313.672862,25.6861616 C305.089562,25.6861616 288.79404,37.0951515 266.88963,59.0208081 C249.818636,76.1449158 229.943199,99.4834175 208.984226,128.54766 Z M631,197.086582 C606.662946,221.317407 530.783603,287.91234 510.695707,343.958737 L485.827508,337.553131 C493.954024,314.342104 518.429175,278.245505 545.719394,250.38165 C539.919293,252.580589 533.85362,253.387929 528.998956,253.387929 C521.626667,253.387929 515.890303,251.167744 512.448485,246.982323 C509.962727,243.976044 508.709226,240.045572 508.709226,235.382121 C508.709226,234.372946 508.783586,233.342525 508.921684,232.205875 C484.967054,246.791111 465.686498,253.387929 446.820236,253.387929 C432.139394,253.387929 419.763721,246.982323 414.069848,235.764545 C390.274562,247.55596 367.477828,253.387929 348.399108,253.387929 C330.648249,253.387929 316.349832,246.366195 309.784882,233.54436 C285.734646,247.067306 265.285572,253.387929 249.011296,253.387929 C239.641902,253.387929 232.216498,250.78532 227.436195,245.877542 C223.93064,242.265758 222.071633,237.379226 221.816684,231.749091 C206.392239,241.893956 183.892946,253.387929 160.777525,253.387929 C137.173451,253.387929 121.324091,245.272037 109.033401,237.251751 C89.4235354,248.097727 67.8590572,253.387929 45.0517003,253.387929 C27.8107407,253.387929 0,246.196229 0,221.487374 C0,201.526953 20.8208754,188.025253 48.6634848,188.025253 C72.3525421,188.025253 95.1705219,198.010774 109.490185,208.357475 C123.087492,197.543367 137.35404,182.395118 154.170084,161.011229 C150.473316,161.202441 146.861532,161.30867 143.313485,161.30867 C111.08362,161.30867 84.1758249,151.822424 69.4949832,135.18697 C61.570303,126.210623 57.8204209,115.67271 57.8204209,104.338081 C57.8204209,59.5200842 114.408586,24.7513468 163.921902,19.641734 C167.204377,27.0565152 170.136296,32.771633 173.142576,39.5702862 C124.224141,45.2535354 83.4853367,74.2115488 83.4853367,102.50032 C83.4853367,121.090387 104.401818,139.765438 148.76303,139.765438 C156.358401,139.765438 163.996263,139.043081 171.517273,137.991414 C210.673266,83.9421212 270.703249,0 322.330522,0 C337.616869,0 345.594663,9.28441077 345.594663,21.7238215 C345.594663,47.2825084 323.626515,74.7958081 309.306852,89.1473401 C286.796936,111.763485 246.111246,145.395572 189.257508,156.53899 C167.14064,187.292273 148.964865,207.698855 130.789091,222.432811 C141.815657,228.381633 152.130488,232.014663 164.46367,232.014663 C195.046987,232.014663 224.727357,204.002088 247.917138,180.270539 L248.735101,179.484444 L266.815269,193.612896 L265.976061,194.590202 C255.724966,206.349747 246.281212,218.767912 246.281212,225.715286 C246.281212,231.016111 250.732205,232.057155 254.577694,232.057155 C266.30537,232.057155 284.35367,224.48303 305.610084,211.406246 L305.610084,211.225657 C307.957744,158.695438 379.630421,78.3863468 423.141801,78.3863468 C435.421869,78.3863468 442.486094,84.4945118 442.486094,95.2236364 C442.486094,121.547172 397.05197,178.007862 330.988182,221.200556 L330.988182,221.232424 C334.408754,228.583468 342.28032,232.131515 355.6333,232.131515 C366.064983,232.131515 386.429074,227.478687 410.670522,214.816195 C413.485589,187.600337 428.899411,158.387374 448.445539,137.566498 C468.066027,116.713754 490.055421,103.148316 509.070404,103.148316 C520.787458,103.148316 527.713586,109.61766 527.713586,119.741279 C527.713586,142.697357 501.060741,181.959579 436.845337,223.070185 C439.68165,228.583468 445.205556,232.057155 453.778232,232.057155 C472.899444,232.057155 506.595269,211.639949 532.855067,186.538047 L551.700084,201.18702 C543.647929,210.949461 535.510791,221.699832 535.776364,227.861111 C535.840101,229.858215 537.189209,231.186077 540.354832,231.186077 C559.699125,231.186077 590.165589,205.659259 613.004815,183.117475 L631,197.086582 Z M280.805623,144.407643 C289.346431,144.407643 296.251313,151.355017 296.251313,159.874579 C296.251313,168.42601 289.346431,175.362761 280.805623,175.362761 C272.243569,175.362761 265.317441,168.42601 265.317441,159.874579 C265.317441,151.355017 272.243569,144.407643 280.805623,144.407643 Z"></path></svg></a></div></div></div></footer></div></div></div><script nonce="">window.__NUXT__={config:{_app:{basePath:"\u002F",assetsPath:"\u002F_nuxt\u002F",cdnURL:null}}}</script>
  <script src="/_nuxt/8960da8.js" nonce=""></script><script src="/_nuxt/2f68ebb.js" nonce=""></script><script src="/_nuxt/2e3bd81.js" nonce=""></script><script src="/_nuxt/c9d1dc4.js" nonce=""></script>

<link href="/_nuxt/css/6eeb884.css" rel="stylesheet" type="text/css"><img src="https://pt.ispot.tv/v2/TC-3563-1.gif?app=web&amp;type=visit" style="display:none" alt="">
<script type="text/javascript" id="">try{(function(){var a=google_tag_manager["GTM-PWPQ494"].macro(9);a="undefined"==typeof a?google_tag_manager["GTM-PWPQ494"].macro(10):a;var b=new Date;b.setTime(b.getTime()+18E5);var c="gtm-session-start";b=b.toGMTString();var d="/";document.cookie=c+"\x3d"+a+"; Expires\x3d"+b+"; Path\x3d"+d})()}catch(a){};</script><script type="text/javascript" id="">(function(){if("undefined"===typeof google_tag_manager["GTM-PWPQ494"].macro(11)){var f="PageNumber",e=0,d="/",a=1800;a*=1E3;var b=new Date,c=b.getTime();b.setTime(c+a);a=b.toUTCString();document.cookie=f+"\x3d"+e+"; expires\x3d"+a+"; path\x3d"+d}f="PageNumber";e=parseInt;a:{d="PageNumber\x3d";a=document.cookie.split(";");for(b=0;b<a.length;b++){for(c=a[b];" "==c.charAt(0);)c=c.substring(1,c.length);if(0==c.indexOf(d)){d=c.substring(d.length,c.length);break a}}d=null}e=1+e(d);d="/";a=1800;a*=1E3;b=new Date;c=b.getTime();
b.setTime(c+a);a=b.toUTCString();document.cookie=f+"\x3d"+e+"; expires\x3d"+a+"; path\x3d"+d})();</script>
 
<script type="text/javascript" id="">dataLayer.push({event:"checkcomplete"});</script><script type="text/javascript" id="" src="//d22xmn10vbouk4.cloudfront.net/578f3ef6d91811ebad63dca9047d4cc8.js"></script>
<script type="text/javascript" id="" src="https://w.soundcloud.com/player/api.js"></script>

<script type="text/javascript" id="">(function(){try{var t=function(d){var a,b,l,m,n,e,f,h="SoundCloud",c=SC.Widget(d);c.bind(SC.Widget.Events.READY,function(){c.getCurrentSound(function(g){f=g.title});c.bind(SC.Widget.Events.PLAY,function(){a="Play";k(h,a,f)});c.bind(SC.Widget.Events.PAUSE,function(g){b=Math.round(100*g.relativePosition);100!==b&&(a="Pause",k(h,a,f))});c.bind(SC.Widget.Events.PLAY_PROGRESS,function(g){e=!1;b=Math.round(100*g.relativePosition);25!==b||l||(a="25%",e=l=!0);50!==b||m||(a="50%",e=m=!0);75!==b||n||(a="75%",
e=n=!0);e&&k(h,a,f)});c.bind(SC.Widget.Events.FINISH,function(){a="100%";l=m=n=!1;k(h,a,f)})})},k=function(d,a,b){window.dataLayer.push({event:"scEvent",eventCategory:d,eventAction:a,eventLabel:b})},q,r=document.querySelectorAll('iframe[src*\x3d"api.soundcloud.com"]');var p=0;for(q=r.length;p<q;p+=1)t(r[p])}catch(d){console.log("Error with SoundCloud API: "+d.message)}})();</script></body></html>